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ABSTRACT	
	
The	Impact	of	Race	and	Diabetes	on	Mortality	among	Breast	Cancer	Patients		
	
By	
	
Jibril	Mubarak	Ibn	Abdu	Alim	
	
April	26,	2017	
	
	
	
INTRODUCTION:		Breast	cancer	and	Type	2	diabetes	Mellitus	are	two	chronic	conditions	that	
impact	the	lifespan	and	quality	of	life	of	women.	Both	diabetes	and	breast	cancer	have	a	
disproportionate	impact	on	African-American/Black	women	and	it	is	reasonable	to	believe	that	
Biological	mechanisms	or	treatments	for	this	co-morbid	condition	may	have	an	antagonistic	
effect	and	impact	the	individual’s	risk	of	mortality.	
	
AIM:	This	study	aims	to	address	whether	pre-existing	diabetes	occurs	at	different	rates	among	
African-American/Black	women	with	breast	cancer	than	White	women,	and	if	diabetes	and	race	
are	associated	with	higher	all-cause	and	breast	cancer	specific	mortality	among	women.	
	
METHODS:	The	US	mortality	linked	data	from	the	National	Health	Interview	Survey	(NHIS)	
2006-2009,	was	used	in	the	analysis.	Cox	proportional	hazard	regression	was	used	to	model	and	
estimate	the	adjusted	and	unadjusted	hazard	ratios	of	the	identified	risk	factors	on	mortality.	
	
RESULTS:	Diabetes	and	pre-existing	diabetes	(33.20%	&	52.24%)	were	more	prevalent	among	
Black	women	with	breast	Cancer	than	Whites	(13.87%	&	39.82%).	African-Americans	
experienced	increased	breast	cancer	specific	mortality	(HR:	1.564,	1.465-1.669	95%CI)	than	
whites.	Diabetes	and	Pre-diabetes	were	associated	with	increased	risk	of	all-cause	(HR:	1.60	&	
1.329)	and	breast	cancer	specific	mortality	(HR:	1.37	&	1.177).	Diabetes	and	pre-diabetes	
impacted	all-cause	mortality	among	Africans-Americans	(HR:	15.757	&	13.658)	differentially	
than	Whites	(HR:	1.377	&	1.079).	Similarly,	Diabetes	and	pre-diabetes	impacted	breast	cancer-
specific	mortality	among	African-Americans	(HR:	10.891	&	7.696)	differentially	than	whites	(HR:	
1.125	&	0.850)	
	
DISCUSSION:	Diabetes	and	breast	cancer	was	a	more	common	comorbidity	among	Black	
women	than	Whites.	Diabetes	was	associated	with	increased	risk	of	all	cause	and	breast	cancer	
specific	death.	Race	was	found	to	have	a	significantly	increase	breast	cancer	specific	mortality	
among	diabetic	individuals.	Increased	diabetes	prevalence	among	Blacks	may	partially	explain	
their	higher	breast	cancer	mortality	rates.		
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Chapter	I		
Introduction	
	
Both	breast	cancer	and	type	2	diabetes	mellitus	(T2DM)	are	growing	health	concerns	for	
aging	women	in	the	United	States.	Breast	cancer	is	the	second	most	common	cancer	among	
women	with	about	12.4%	of	women	developing	breast	cancer	during	their	lifetime	(SEER,	
2013).	Breast	cancer	is	the	second	leading	cause	of	cancer	death	among	women	in	the	US	with	
over	40,860	deaths	each	year	(CDC,	2013).	The	risk	of	being	diagnosed	with	breast	cancer	
increases	with	age	and	the	average	age	of	diagnosis	in	the	United	States	is	61	(CDC).	
Per	current	data	released	by	the	CDC,	5.9%	of	adult	women	in	the	US	had	diabetes	in	
2014,	this	rate	has	more	than	doubled	since	1980	when	the	rate	for	women	was	2.9%.	The	risk	
of	having	diabetes	increases	with	age;	in	2014	the	rate	in	the	0-44	age	group	was	1.5%,	12%in	
the	45-64	age	group,	21.5%	in	the	65-74	age	group,	and	19.2%	in	the	75+	age	group.		The	
median	age	of	diabetes	diagnosis	for	women	is	55.2	(CDC,	2011).		
A	growing	trend	in	the	United	States	is	that	of	patients	with	multiple	coexisting	diseases	
termed	comorbidities.	According	to	the	CDC,	one	in	four	Americans	has	multiple	chronic	
conditions	(DHHS	2014),	and	three	in	four	Americans	over	the	age	of	65	have	multiple	chronic	
conditions	(AHRQ	2014).	Based	on	Medicare	claims	data,	42%	of	patients	with	breast	cancer	
had	one	or	more	comorbidities	at	the	time	of	diagnosis	(Wu,	et	al.,	2015).	Comorbidities	are	
associated	with	complex	clinical	management,	increased	health	care	costs,	and	poorer	health	
		 9	
outcomes	including	mortality	and	low	quality	of	life.		Comorbid	conditions	may	make	the	
diagnosis	of	another	disease	more	difficult	by	obscuring,	preventing,	or	delaying	proper	
screening.	The	biological	mechanisms	for	the	coexisting	conditions	may	interact	to	worsen	the	
individual’s	health.	The	treatment	for	one	disease	also	may	have	an	antagonistic	effect	on	a	
coexisting	disease.	These	potential	effects	combine	to	impact	the	individual’s	risk	for	mortality.		
Both	diabetes	and	breast	cancer	have	a	disproportionate	effect	on	black	women	in	
comparison	to	other	ethnicities.	Cancer	is	the	second	leading	cause	of	death	among	African-
Americans,	accounting	for	22.6%	of	deaths	of	all	African-American	women	(CDC,	2013).	Black	
women	in	the	US	suffer	from	higher	breast	cancer	mortality	rates	than	any	other	ethnicity	and	
because	of	the	high	prevalence	of	diabetes	within	African-American	women,	it	is	reasonable	to	
consider	that	this	co-morbid	condition	may	influence	clinical	outcomes.	Furthermore,	for	a	
variety	of	socioeconomic,	behavioral,	and	biological	reasons,	the	comorbid	condition	of	
simultaneous	diabetes	and	breast	cancer	may	have	different	effects	on	clinical	outcomes	across	
racial	ethnic	groups.		
To	improve	prevention	and	clinical	management	it	is	critical	that	researchers	
understand	how	multiple	conditions	may	interact	to	affect	the	health	of	the	patient	and	how	
this	interaction	may	vary	by	demographic	group.		
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Background	
	
Diabetes	
Type	2	diabetes	mellitus,	is	a	chronic	disease	in	which	the	body’s	ability	to	produce	or	
respond	to	the	hormone	insulin	is	impaired,	resulting	in	abnormal	metabolism	of	carbohydrates	
and	elevated	levels	of	glucose	in	the	blood	and	urine	(ADA).	Type	2	diabetes	mellitus	is	caused	
by	a	combination	of	resistance	to	insulin	action	and	an	inadequate	insulin	secretory	response	
(ADA).	
The	chronic	hyperglycemia	of	diabetes	can	cause	severe	long-term	damage,	dysfunction,	
and	failure	of	various	organs;	the	eyes,	kidneys,	nerves,	heart,	and	blood	vessels.	These	
complications	include	retinopathy	with	loss	of	vision,	nephropathy	leading	to	kidney	failure,	
peripheral	neuropathy	leading	to	amputations	in	extremities,	most	commonly	the	foot,	and	
autonomic	neuropathy	causing	gastrointestinal,	genitourinary,	and	cardiovascular	symptoms	
(ADA).	Diabetes	is	the	seventh	leading	cause	of	death	in	the	United	states.	Type	2	diabetes	
which	was	previously	called	non-insulin	dependent	diabetes	mellitus,	type	II	diabetes,	or	adult	
onset	diabetes,	is	estimated	to	account	for	about	90%	to	95%	of	all	diagnosed	cases	of	
diabetes.	Type	2	diabetes	often	goes	undiagnosed	for	many	years	because	hyperglycemia	
progresses	gradually	and	at	early	stages	is	asymptomatic.	The	risk	of	developing	this	form	of	
diabetes	increases	with	age,	obesity,	and	lack	of	physical	activity.		
Type	2	diabetes	is	often	associated	with	a	strong	genetic	predisposition	however	the	
genetics	are	complex	and	not	clearly	understood.	Known	risk	factors	that	increase	the	
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likelihood	of	developing	diabetes	include	being	overweight	or	obese,	family	history	of	diabetes,	
genetic	predisposition	linked	to	race/ethnicity,	prior	history	of	gestational	diabetes,	
hypertension,	abnormal	cholesterol	levels,	and	being	physically	inactive	(CDC	2015).		
Among	females,	African-American	women	have	notably	high	rates	of	diabetes	with	a	
prevalence	of	9.9%.	This	is	followed	by	women	of	Hispanic	origin	whose	rates	range	from	8.1%	
to	9.6%.	Black	women	are	diagnosed	at	a	younger	age	with	diabetes	than	all	other	ethnicities	at	
a	median	age	of	49,	compared	to	55.4	for	white	women.		
	
Breast	Cancer	
	
Breast	cancer	is	a	disease	in	which	the	cells	in	breast	tissue	grow	out	of	control.	Breast	
cancer	is	conceptually	referred	to	as	a	single	disease	however	it	is	distinguished	by	21	distinct	
histological	subtypes	and	4	molecular	subtypes	that	differ	in	presentation,	response	to	
treatment,	and	outcomes.	Breast	cancer	is	characterized	both	by	the	origin	of	the	cancerous	
cells	and	the	spread	of	the	cells,	termed	in	situ	or	invasive.	There	are	three	main	tissues	of	
breasts;	the	lobules,	ducts,	and	connective	tissue.	The	Most	cancers	begin	in	the	ducts	or	
lobules.	Malingnancies	termed	as	“in-situ”	are	carcinoma	where	the	cancerous	cells	do	not	
grow	beyond	the	layer	of	cells	in	which	they	originated,	whereas	invasive	carcinoma	have	
spread	into	other	tissues	within	the	breast.	The	most	common	kinds	of	breast	cancer	are	
invasive	ductal	carcinoma	where	cancer	cells	grow	outside	the	ducts	into	other	parts	of	the	
breast	tissue,	and	invasive	lobular	carcinoma	where	cancer	cells	spread	from	the	lobules	to	
nearby	breast	tissues.			
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An	additional	method	of	classification	of	breast	cancers	is	the	cancer	cells’	susceptibility	
to	hormone	treatment.	In	triple-negative	breast	cancer,	breast	cancer	cells	don’t	have	estrogen	
or	progesterone	receptors	and	don’t	have	significant	levels	of	the	HER2	protein.	This	results	in	a	
breast	cancer	subtype	that	is	extremely	resistant	to	treatment.	Triple-negative	breast	cancer	
also	grows	and	spreads	faster	than	most	other	types	of	breast	cancer.		
Risk	factors	for	breast	cancer	include	getting	older,	genetic	mutations,	early	menstrual	
period,	late	or	no	pregnancy,	starting	menopause	after	age	55,	not	being	physically	active,	
being	overweight	or	obese	after	menopause,	having	dense	breasts,	using	combination	hormone	
therapy,	taking	oral	contraceptives,	personal	or	family	history	of	breast	cancer,	previous	
treatment	using	radiation	therapy,	and	drinking	alcohol.	
Black	women	have	a	breast	cancer	incidence	rate	of	124	per	100,000	which	is	slightly	
lower	than	that	incidence	rate	of	white	women	(128.1),	but	is	higher	than	other	minorities	such	
as	Hispanics,	Asians/Pacific	Islanders,	and	American	Indians/Alaskan	Natives.	However,	the	
death	rate	for	black	women	with	breast	cancer	at	31.0	per	100,000	is	higher	than	the	death	
rate	for	white	women	(21.9	per	100,000)	and	other	ethnicities,	15.0	for	AI/AN,	14.5	for	
Hispanic,	and	11.4	for	Asian/Pacific	Islander	(CDC	2015).	The	prevalence	of	more	aggressive	
cancer	subtypes	such	as	triple	negative	breast	cancers	are	more	common	among	African-
American	women	than	other	ethnicities,	and	nearly	twice	as	common	than	in	white	women.	
The	high	prevalence	of	these	aggressive	sub-types	contributes	to	mortality	disparities.		
	
Diabetes	and	Breast	Cancer	interaction	
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The	current	literature	has	reported	mixed	findings	on	the	significance	of	diabetes	on	risk	of	
breast	cancer	specific	and	all-cause	mortality.	Racial	differences	in	the	diabetes-breast	cancer	
interaction	have	not	been	thoroughly	explored.	There	have	been	few	studies	that	have	
analyzed	racial	differences	in	the	relationship	between	diabetes	and	breast	cancer	mortality;	
one	focusing	on	the	comparison	of	Hispanic	women	with	non-Hispanic	white	women	and	one	
on	African-American	women.		
Investigating	the	link	between	diabetes	and	mortality	in	breast	cancer	patients	can	
elucidate	whether	the	higher	mortality	observed	in	diabetic	breast	cancer	patients	is	due	to	
poor	prognosis	specific	to	breast	cancer	or	due	to	competing	risk.	Investigating	racial	
differences	in	the	effect	of	pre-existing	diabetes	on	all	cause	and	breast	cancer	specific	
mortality	may	help	explain	disparities	in	breast	cancer	mortality.	Additionally,	findings	from	this	
study	may	help	guide	policy	for	prevention	efforts	and	clinical	management	guidelines	for	
women	exhibiting	this	co-morbidity.		Currently	there	are	no	clinical	guidelines	that	focus	on	
treating	patients	with	cancer	and	other	co-occurring	diseases.	Understanding	the	associations	
between	diabetes	and	cancer	mortality	can	contribute	toward	improving	cancer	screening	and	
assessment	practices.	
	
Research	Questions	and	Hypotheses	
	
Using	data	from	the	National	Health	Interview	Survey	(NHIS),	this	study	will	address	the	
following	research	questions:		
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1) Does	diabetes	and	pre-existing	diabetes	occur	at	different	rates	among	African-
American	women	with	breast	cancer	than	White	women	in	the	US?		
Ha:	African-American	women	have	significantly	higher	prevalence	of	diabetes	
and	pre-existing	diabetes	than	white	women.		
2) Among	women	with	both	breast	cancer	and	diabetes,	Is	diabetes	and	preexisting	
diabetes	associated	with	higher	all-cause	mortality	rates	among	African-American	
women	with	breast	cancer	than	other	ethnicities?		
Ha:	African-American	women	with	diabetes	have	higher	all-cause	mortality	than	
white	women.	
3) Among	women	with	both	breast	cancer	and	diabetes,	Is	diabetes	and		pre-existing	
diabetes	associated	with	higher	breast	cancer	specific	mortality	rates	among	African-
American	women	with	breast	cancer	than	other	ethnicities?		
Ha:	African-American	women	who	have	breast	cancer	and	diabetes	have	
significantly	different	breast	cancer	specific	mortality	rates	than	white	women.		
4) Among	women	with	both	breast	cancer	and	diabetes,	is	race	associated	with	increased	
all-cause	mortality?	
Ha:	The	racial	classification	of	African-American/Black	is	associated	with	
increased	all-cause	mortality.		
5) Among	women	with	both	breast	cancer	and	diabetes,	is	race	associated	with	increased	
breast	cancer	specific	mortality?	
Ha:	The	racial	classification	of	African-American/Black	is	associated	with	
increased	breast	cancer	specific	mortality.		
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6) Does	the	impact	of	diabetes	and	pre-existing	diabetes	on	all-cause	mortality	differ	
among	African-American	and	White	breast	cancer	patients?	
Ha:	Diabetes	and	pre-diabetes	are	associated	with	higher	all-cause	mortality	
among	African-American	women	than	White	women.		
7) Does	the	impact	of	diabetes	and	pre-existing	diabetes	on	breast	cancer	specific	
mortality	differ	among	African-American	and	White	breast	cancer	patients?	
Ha:	Diabetes	and	pre-diabetes	are	associated	with	higher	breast	cancer	specific	
mortality	among	African-American	women	than	White	women.		
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Chapter	II	
Review	of	the	Literature	
	
Black	women	and	breast	cancer	
	
Black	women	have	40%	higher	breast	cancer	mortality	rates	than	white	women.	The	
disparity	in	breast	cancer	mortality	between	black	women	and	white	women	has	grown	since	
1979	when	the	mortality	rate	ratio	between	the	groups	was	1.39,	compared	to	more	recent	
mortality	rate	ratio	estimates	in	2010	of	2.00	(McCarthy,	Yang,	&	Armstrong,	2015).	Age	is	a	
well-established	risk	factor	for	the	development	of	all	cancers,	however	cancer	has	been	shown	
to	generally	develop	earlier	in	some	racial/ethnic	groups.	The	average	age	of	breast	cancer	
diagnosis	for	African	American	women	is	57	compared	to	an	average	of	62	for	white	women	
(Newman,	2015).	The	impact	of	age	is	even	more	evident	when	cancer	incidence	and	mortality	
is	analyzed	at	the	age-group	level.	Young	black	women	in	the	20-49	age	group	have	higher	
breast	cancer	incidence	rates	than	white	women.	Additionally,	a	study	using	data	from	the	
National	Center	for	Health	Statistics	reported	that	among	women	aged	20-49	the	breast	cancer	
mortality	rate	was	2	times	greater	among	black	women	when	compared	to	white	women	
(McCarthy,	et	al.,	2015).		
A	study	based	on	the	California	Breast	Cancer	Survivorship	Consortium	(CBCSC)	which	
included	2,060	black	women,	indicated	there	are	racial/ethnic	differences	in	some	
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sociodemographic	and	lifestyle	characteristics	of	breast	cancer	patients.	Compared	to	non-
Hispanic	white	women,	African	American	women	with	breast	cancer	were	less	educated,	more	
likely	to	be	multiparous,	younger	at	age	of	first	birth,	and	have	higher	rates	of	first-degree	
family	history	of	breast	cancer	(Wu,	et	al.,	2013).	Low	neighborhood	SES	is	more	common	in	
African	American	breast	cancer	patients	compared	to	non-Hispanic	white	breast	cancer	
patients.	Additionally,	tumor	characteristics	that	are	associated	with	poor	survival	such	as	
Cancer	stage,	grade,	ER-/PR	status,	nodal	involvement,	and	tumor	size	were	found	to	be	worst	
in	African-Americans	compared	to	other	racial/ethnic	groups	(Wu,	et	al.,	2013).		
Because	few	modifiable	risk	factors	have	been	identified	for	breast	cancer,	persistent	
disparities	suggest	that	there	are	differences	breast	cancer	biology,	prevention,	and	treatment.	
When	racial	disparities	in	mortality	rates	were	first	discovered	racial	differences	in	
mammography	screening	were	posited	as	the	explanation	for	higher	mortality	rates	among	
ethnic	groups.	However,	estimates	show	that	although	screening	rates	for	black	women	were	
lower	in	the	1980’s	and	90’s,	the	gap	has	shrunk	considerably	since	and	currently	Black	women	
have	comparable	or	higher	screening	rates	across	all	age	groups	(McCarthy,	et	al.,	2015).	
Studies	have	shown	that	breast	cancer	treatments	display	similar	efficacy/effectiveness	across	
different	racial/ethnic	groups	however,	treatment	prevalence	differs.		Breast-conserving	
surgery	rates	in	black	women	have	been	shown	to	lag	behind	the	utilization	rates	of	similarly	
staged	white	women	(Shavers	&	Brown,	2002).	Additionally,	findings	suggest	that	African-
Americans	less	frequently	receive	radiation	therapy	after	breast-conserving	surgery		(Shavers	&	
Brown,	2002).	Population	based	studies	have	revealed	patterns	of	treatment	failure	on	Ductal	
Carcinoma	In	Situ	(DCIS)	related	to	racial/ethnic	identity.	SEER	based	analyses	report	a	35%	
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higher	mortality	for	African-American	women	compared	to	white	women.	As	well	as	an	
increased	risk	of	invasive	and	advanced	recurrences	among	African-American	women	
(Newman,	2015).		
Evidence	suggests	that	tumor	biology	may	differ	based	on	race/ethnicity.	Disparities	in	
mortality	between	African-American	women	and	white	women	emerged	when	tamoxifen	
became	a	popular	therapy	for	breast	cancer.	Tamoxifen	has	been	shown	to	be	very	effective	in	
women	with	hormone	receptor	positive	forms	of	breast	cancer,	but	ineffective	in	treating	
hormone	receptor	negative	breast	cancers.	Hormone	receptor	negative	breast	cancers	are	
more	prevalent	in	black	women,	specifically,	the	triple	negative	breast	cancer	phenotype	
accounts	for	15%	of	all	breast	cancers	among	white	women,	and	30%	of	all	breast	cancers	
among	African-American	women	(Newman,	2015).	Analysis	of	the	California	cancer	registry	
shows	that	non-Hispanic	white	women	have	a	higher	proportion	than	African-American	women	
of	luminal	cancers,	being	defined	as	ER-positive	and/or	PR	positive	(71.6%	vs	53%)	(Daly	&	
Olopade,	2015).	Similarly,	a	study	using	SEER	registries	found	that	17.2%	of	African-American	
women	had	triple-negative	breast	tumors	compared	to	8.0%	of	non-Hispanic	white	women	
(Daly	&	Olopade,	2015).	International	studies	have	revealed	that	women	from	sub-Saharan	
African	countries	have	higher	rates	of	triple-negative	breast	cancer	compared	to	other	nations	
in	the	world	(Newman,	2015).		
	
Black	women	and	diabetes	
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Diabetes	mellitus	is	among	the	most	common	life	and	health	threatening	chronic	
diseases.	There	are	established	racial/ethnic	disparities	associated	with	inequities	in	diabetes	
control	and	rates	of	diabetes	related	complications.	Many	factors	contribute	to	this	including	
lifestyle	and	behaviors,	biophysiological,	psychosocial,	sociodemographic,	and	environmental	
factors,	as	well	as	biogeographic	ancestry.		
The	prevalence	of	type	2	diabetes	among	African-American	women	is	double	that	of	
white	women	and	approximately	40%	greater	than	that	of	African-American	men	(Flegal,	et	al.,	
2012).	Obesity	is	the	strongest	modifiable	risk	factor	for	diabetes	and	is	more	prevalent	among	
African-American	women	than	other	ethnic	groups	(Zimmet,	Alberti,	&	Shaw,	2001).	Black	
women	are	less	likely	to	report	regular	exercise	than	other	racial/ethnic	groups.		
	In	addition	to	prevalence,	there	are	also	racial/ethnic	disparities	in	long	term	
complications	that	result	from	diabetes.	Rates	of	end-stage	kidney	disease	are	4	times	higher	
among	African-Americans	compared	to	those	of	non-Hispanic	whites.	Rates	of	retinopathy	are	
twice	as	high	in	African-Americans	than	in	non-Hispanic	whites	(Osborn,	Groot,	&	Wagner,	
2013).		This	disparity	in	prevalence	of	diabetic	retinopathy	is	associated	with	factors	that	
influence	diabetes	severity	(duration	of	diabetes,	HbA1c	levels,	and	treatment	with	insulin	and	
oral	agents).	In	a	National	Health	and	Nutrition	Survey	(NHANES)	study,	ethnic	disparities	of	
diabetes	control	were	identified.		A	larger	proportion	of	non-Hispanic	black	women	with	
diabetes	were	treated	with	insulin	alone	(39.8%)	than	both	non-Hispanic	white	women	(31.4%)	
and	Mexican-American	women	(26.6%)	indicating	more	severe	diabetes	among	non-Hispanic	
black	women.	This	study	revealed	that	non-Hispanic	black	women	with	diabetes	had	
substantially	higher	HbA1c	levels	(p<0.01)	than	other	diabetic	groups.	Logistic	regression	
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modeling	fully	adjusted	for	socioeconomic	variables	indicated	that	compared	to	white	men,	
black	women	were	twice	as	likely	to	have	poor	glycemic	control	(OR	2.01	95%	CI	1.13,	3.58)	
which	was	the	only	significant	OR	identified	and	the	highest	point	estimate	of	all	groups	
analyzed	(Harris,	Eastman,	Cowie,	Flegal,	&	Eberhardt,	1999).	Poor	glycemic	control	is	a	risk	
factor	for	increased	mortality	among	diabetic	patients.	The	risk	of	death	among	people	with	
diabetes	mellitus	is	twice	that	of	people	of	a	similar	age	without	diabetes	mellitus	(Yunhai,	
Xiang,	Chen,	&	Jiazeng,	2015).		
	
Pre-existing	diabetes	and	Breast	cancer	
	
The	interactions	between	breast	cancer	and	diabetes	are	very	complex.	Diabetes	may	
play	a	role	in	the	development	of	breast	cancer.	People	with	diabetes	have	an	estimated	27%	
higher	risk	of	breast	cancer	incidence	than	non-diabetics	(Boyle,	et	al.,	2012).	A	study	
performed	using	longitudinal	CMS	linked	data	from	the	Women’s	Health	Initiative	(WHI)	found	
that	10.6%	of	women	diagnosed	with	invasive	breast	cancer	had	pre-existing	diabetes	(J.	Luo,	et	
al.,	2015).	A	prospective	cohort	study	of	8,108	women	with	invasive	breast	cancer	found	that	
9%	had	pre-existing	diabetes	prior	to	breast	cancer	diagnosis	(Juhua	Luo,	et	al.,	2014).	This	
same	study	found	that	breast	cancer	patients	with	diabetes	were	significantly	more	likely	to	be	
older,	heavier,	less	educated	and	of	non-white	racial/ethnic	groups.	Pre-diabetes	was	
associated	with	an	increased	risk	for	the	development	of	breast	cancer	in	post-menopausal	
women	but	not	premenopausal	while	diabetes	increased	the	risk	for	breast	cancer	in	both	
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groups	but	showed	a	greater	effect	on	post-menopausal	women	(adjusted	OR	2.41	and	2.85	
respectively)	(Salinas-Martínez,	et	al.,	2014).	Women	with	diabetes	are	more	likely	to	have	
HER2-negative	tumors	and	advanced	tumor	stage	than	women	without	diabetes	(J.	Luo,	et	al.,	
2015).	In	a	study	focused	on	a	racial/ethnic	group	with	high	rates	of	diabetes,	A	case-control	
study	conducted	among	646	Mexican	women	from	2011	to	2013	found	that	42.1%	of	breast	
cancer	patients	reported	having	diabetes,	compared	to	28.6%	of	women	without	breast	cancer	
(Salinas-Martínez,	et	al.,	2014).	
Diabetes	may	adversely	affect	cancer	outcomes	by	influencing	cancer	screening,	
diagnosis,	or	treatment	by	patients	and	physicians.	Underuse	of	breast	cancer	screening	among	
diabetics,	which	may	delay	diagnosis	and	subsequently	lead	to	more	advanced	tumors	and	
poorer	prognosis	is	a	relevant	factor	to	be	considered	(Lipscombe,	Goodwin,	Zinman,	
McLaughlin,	&	Hux,	2008).	Among	breast	cancer	patients,	women	with	diabetes	were	more	
likely	to	have	a	longer	interval	from	the	last	mammogram	to	breast	cancer	diagnosis	than	
women	without	diabetes	(J.	Luo,	et	al.,	2015).	Diabetics	may	also	receive	different	cancer	
treatments	than	non-diabetics	which	may	adversely	affect	survival.	In	a	SEER	based	cohort	
study	of	70,781	men	and	women	with	breast	cancer,	diabetics	had	lower	odds	of	receiving	
anthracyclines	OR:	0.78	(95%	CI	0.71,	0.87)	and	taxanes	OR	0.86	(95%	CI	0.75,	0.99)	than	non-
diabetics	(Srokowski,	Fang,	Hortobagyi,	&	Giordano,	2009).	Comparisons	of	the	odds	of	
chemotherapy	receipt	for	diabetic	breast	cancer	patients	have	yielded	mixed	results	in	the	
literature,	with	some	studies	indicating	lower	odds	and	others	indicating	no	difference	(Gold,	
Makarem,	Nicholson,	&	Parekh,	2014).	A	study	on	the	WHI	cohort	shows	that	breast	cancer	
patients	with	diabetes	are	less	likely	to	receive	radiation	treatment	than	women	without	
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diabetes	(J.	Luo,	et	al.,	2015).	Overall,	breast	cancer	patients	with	comorbidities	are	less	likely	
to	treated	with	radiotherapy	and	axillary	node	dissection	(Lipscombe,	et	al.,	2008).	Breast	
cancer	patients	with	diabetes	have	been	shown	to	have	higher	rates	of	surgical	site	infection	
and	hospitalization	for	chemotherapy	complications	(Gold,	et	al.,	2014).	Once	receiving	
chemotherapy,	patients	with	diabetes	were	more	likely	to	be	hospitalized	for	complications	
than	patients	without	diabetes.	Pre-clinical	studies	have	suggested	that	the	diabetes	
medication	metformin	may	decrease	breast	cancer	progression	and	aid	in	both	overall	survival	
(estimated	HR:	0.53)	as	well	as	breast	cancer	specific	survival	(estimated	HR:	0.89)	(Xu,	et	al.,	
2015).	
The	potential	link	between	diabetes	mellitus	and	cancer	development	has	been	
hypothesized	to	be	related	to	hormonal,	inflammatory,	or	metabolic	characteristics	of	poorly	
controlled	diabetes	mellitus(Yunhai,	et	al.,	2015).	Hyperinsulemia	and	insulin	resistance	are	two	
physiological	manifestations	of	type	2	diabetes	mellitus.	Cancer	cells	overexpress	insulin	and	
the	IGF-1	receptors.	The	Insulin/IGF	axis	is	thought	to	be	a	critical	interaction	in	diabetes	
associated	risk	and	progression	of	cancer	(Yunhai,	et	al.,	2015).	Hyperinsulemia	could	increase	
the	levels	of	bioactive	oestrogens	by	reducing	the	circulating	sex	hormone	binding	protein	in	
diabetic	women.	Increased	bioactive	oestrogen	stimulates	the	proliferation	of	breast	cells	and	
the	inhibition	of	apoptosis	to	increase	cancer	risk	(Yunhai,	et	al.,	2015).		
Hyperglycemia	may	also	increase	cancer	risk.	Indirectly,	hyperglycemia	induces	the	
production	of	circulating	growth	factors	and	inflammatory	cytokines.	Hyperglycemia	directly	
increases	tumor	cell	proliferation,	inducing	mutations,	augmenting	invasion,	and	migration.	
High	glucose	can	enhance	Wnt/β-catenin	signaling	pathway	which	promotes	cancer	
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development	and	progression	(Yunhai,	et	al.,	2015).	Uncontrolled	diabetes	can	produce	
inflammatory	conditions	in	the	body.	Chronic	inflammation	can	promote	genetic	instability	and	
is	associated	with	increased	cancer	risk.	Some	studies	have	failed	to	observe	a	significant	
association	between	blood	glucose	control	as	indicated	by	Hba1c	and	tumor	stage.	In	a	cohort	
study	conducted	by	Jousheghany	et.	Al,	no	significant	difference	was	found	in	survival	between	
groups	of	breast	cancer	patients	with	HbA1c	<	6.5%	and	HbA1c	>	6.5%	(Jousheghany,	Phelps,	
Crook,	&	Hakkak,	2016),	however	this	study’s	conclusions	are	limited	due	to	small	sample	size	
(n=88).		
Diabetes	and	breast	cancer	share	several	risk	factors	in	their	development.	Obesity	is	
posited	to	be	the	primary	shared	risk	factor	between	diabetes	and	breast	cancer.	However,	it	
has	been	proposed	that	in	obese	women,	diabetes	is	so	frequent	that	it	does	not	allow	for	
discrimination	of	breast	cancer	risk	(Salinas-Martínez,	et	al.,	2014).	In	fact,	in	studies	linking	
type	2	diabetes	to	breast	cancer	risk,	obesity	mitigates	the	magnitude	of	the	association	
between	diabetes	and	breast	cancer(Maskarinec,	et	al.,	2017).	Obesity	is	a	well	established	risk	
factor	for	breast	cancer	in	postmenopausal	women	and	is	associated	with	development	of	
diabetes	as	well.	Obesity	also	is	associated	with	poorer	overall	survival	and	increased	risk	of	
recurrence	in	women	with	breast	cancer.	A	population	based	cohort	study	in	China	found	that	
obesity	before	diagnosis	with	breast	cancer	was	associated	with	a	hazard	ratio	of	1.55	(95%	CI	
1.10,	2.17)	compared	to	women	at	normal	weight.	Similarly,	women	who	gained	weight	from	
pre-	cancer	diagnosis	to	post-	cancer	diagnosis	had	a	hazard	ratio	of	1.71	(95%	CI	1.12,	2.60)	for	
total	mortality	and	1.90	(95%	CI	1.23,	2.93)	for	breast	cancer	specific	mortality	(Chen,	et	al.,	
2010).	
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Studies	have	demonstrated	that	diabetic	breast	cancer	patients	have	an	increased	risk	
of	all-cause	mortality.	Women	with	breast	cancer	who	have	diabetes	have	higher	mortality	(HR:	
1.57,	95%	CI	1.23,	2.01)	than	women	with	breast	cancer	without	diabetes	(J.	Luo,	et	al.,	2015).	
This	study	using	the	WHI	cohort	showed	that	women	with	diabetes	had	significantly	increased	
risk	of	overall	mortality	after	adjusting	for	demographic	and	traditional	risk	factors,	factors	
related	to	delayed	detection,	cancer	treatments,	and	tumor	markers	(J.	Luo,	et	al.,	2015).	
Similarly,	this	study	shows	that	the	distribution	of	cause	of	death	differed	between	groups	of	
diabetic	and	non-diabetic	breast	cancer	patients.	In	the	non-diabetic	group	36.7%	of	the	deaths	
were	due	to	breast	cancer,	17.8%	were	from	other	cancers,	18.4%	from	cardiovascular	disease,	
19.6%	from	other	known	causes,	and	7.5%	from	unknown	causes.	In	the	diabetic	group	26%	of	
deaths	were	from	breast	cancer,	12.7%	from	other	cancers,	23.2%	from	cardiovascular	disease,	
29.8%	from	other	known	causes	and	8.3%	from	unknown	causes.	However,	there	was	a	noted	
difference	in	the	proportion	of	deaths	noted	in	each	group,	20.3%	of	non-diabetics	and	24.9%	
of	diabetics	(Juhua	Luo,	et	al.,	2014).	This	corresponded	with	an	adjusted	HR	of	1.26	(95%	CI	
1.06,	1.48)	for	all-cause	mortality	comparing	diabetics	to	non-diabetics.	In	a	cohort	study	of	
women	with	breast	cancer	using	population	based	health	databases	in	Ontario,	Canada,	
diabetes	was	associated	with	a	significant	decrease	in	survival.	30.9%	of	breast	cancer	patients	
with	diabetes	died	during	the	study	period,	compared	to	21.9%	among	women	without	
diabetes.	This	corresponded	with	a	HR	of	1.39	(96%	CI	1.22,	1.59).		
Additionally,	diabetic	women	may	have	lower	breast	cancer	survival	and	greater	breast	
cancer	mortality.	Few	studies	have	examined	the	impact	of	diabetes	on	breast	cancer	specific	
mortality.	Results	have	been	inconsistent,	and	needs	to	be	further	investigated	to	elucidate	
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whether	the	higher	mortality	is	due	to	a	poorer.	WHI	study	showed	insignificantly	increased	risk	
for	breast	cancer-specific	mortality	among	women	with	diabetes	(J.	Luo,	et	al.,	2015).	In	
another	WHI	study	an	insignificant	relationship	between	diabetes	and	mortality	was	observed,	
with	an	adjusted	HR	of	0.74	(95%	CI	0.52,	1.02)	which	interestingly	appears	to	suggest	potential	
for	diabetes	decreasing	the	risk	for	death	due	to	breast	cancer	(Juhua	Luo,	et	al.,	2014).	In	a	
population	based	cohort	study	in	Ontario,	Canada		no	significant	interaction	between	diabetes	
and	survival	time	was	observed	(Lipscombe,	et	al.,	2008).	These	results	may	be	due	to	the	study	
having	limited	power	to	detect	a	significant	association	due	to	small	number	of	breast	cancer	
deaths.	In	a	study	using	a	SEER	cohort	of	men	and	women	with	breast	cancer,	diabetes	was	
found	to	impact	breast	cancer	specific	mortality	based	on	treatment.	Diabetic	patients	who	did	
not	receive	chemotherapy	had	similar	breast	cancer	specific	mortality,	however,	diabetic	
patients	who	did	receive	chemotherapy	had	higher	breast	cancer	specific	mortality	than	non-
diabetic	patients	with	an	associated	OR	of	1.20	(95%	CI	1.07,	1.35)	(Srokowski,	et	al.,	2009).	
	
Breast	cancer,	diabetes,	and	black	women	
	
Studies	have	found	that	breast	cancer	patients	with	diabetes	are	significantly	more	
likely	to	be	of	non-white	race/ethnicity	groups	(J.	Luo,	et	al.,	2015).	In	a	study	based	off	data	
from	the	California	Breast	Cancer	Consortium,	5.5%	of	breast	cancer	patients	were	found	to	
have	diabetes,	however	comparatively	11.5%	of	all	African-American	breast	cancer	patients	had	
diabetes	which	was	the	highest	among	the	racial/ethnic	groups	(Wu,	et	al.,	2015).	A	case	
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control	in	the	breast	cancer	health	disparities	study	(BCHDS)	consisting	of	NHW	and	
Hispanic/Native	American	women	aged	25-70	found	that	diabetes	history	was	significantly	
associated	with	increased	all-cause	mortality	risk	among	Hispanic	women	(HR	1.64	95%	CI	1.08,	
2.47)	but	not	for	NHW	women	(HR	1.53	95%	CI	0.97,	2.40)	(Connor,	et	al.,	2016).	Similarly,	this	
same	study	found	that	the	association	between	diabetes	and	breast	cancer	specific	mortality	
was	significant	among	Hispanic	women	(HR	1.85	95%	CI	1.11,	3.09)	but	not	for	NHW	(HR	1.33	
95%	CI	0.67,	2.62)	(Connor,	et	al.,	2016).	
To	date,	one	study	has	been	conducted	on	the	relationship	between	diabetes,	breast	
cancer,	and	black	women.	The	Black	Women’s	Health	Study	is	nationwide	a	prospective	cohort	
study	where	1,621	incident	cases	of	invasive	breast	cancer	from	1995	to	2013.	This	study	found	
that	14%	of	black	women	with	breast	cancer	had	diabetes	at	the	time	of	diagnosis.	Women	
with	breast	cancer	who	had	T2DM	were	older	than	women	without	T2DM,	they	were	also	more	
likely	to	be	obese.	A	lower	proportion	of	black	women	with	T2DM	underwent	radiation	
therapy.	The	hazard	ratio	for	black	women	with	T2DM	at	the	time	of	cancer	diagnosis	was	
found	to	be	1.28	(95%	CI	0.88,1.86).	However,	after	categorizing	women	according	to	number	
of	years	between	diagnosis	of	diabetes	and	diagnosis	of	breast	cancer,	a	significant	association	
was	found	for	women	who	had	diabetes	for	at	least	5	years	prior	to	diagnosis	of	cancer	with	a	
HR	of	1.86	(95%	CI	1.05,	3.20).	After	adjusting	for	age	and	SEER	stage,	the	relationship	between	
T2DM	and	breast	cancer	mortality	was	1.07	(95%	CI	0.76,	1.50)	and	for	T2DM	≥	5	years	was	
estimated	at	1.32	(95%	CI	0.91,	1.92).	T2DM	was	significantly	associated	with	al	cause	mortality	
with	a	hazard	ratio	of	1.54	(95%	CI	1.15,	2.07)	and	for	T2DM	≥	5	years	2.26	(95%	CI	1.62,	3.15)	
(Charlot,	et	al.,	2017).	
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Chapter	III	
Methodology	
Data	Sources	
	 NHIS	
The	National	Health	Interview	Survey	(NHIS)	is	a	cross-sectional	household	interview	
survey	conducted	continuously	throughout	each	year.	The	NHIS	is	one	of	the	major	data	
collection	programs	of	the	National	Center	for	Health	Statistics	(NCHS)	which	is	a	part	of	the	
Center	for	Disease	Control	and	Prevention	(CDC).		
The	NHIS	is	one	of	several	continuing	studies	enacted	through	the	National	Survey	Act	
of	1956,	and	has	been	conducted	continuously	since	July	1957.		
The	NHIS	questionnaire	has	Core	questions	and	supplements,	which	collect	basic	
information	on	health	status,	health	care	services,	and	health	behaviors.	The	Core	contains	four	
major	components:	Household,	Family,	Sample	Adult,	and	Sample	Child.	This	study	utilized	only	
the	Sample	Adult	core.	For	the	Sample	Adult	questionnaire,	one	civilian	adult	18	years	or	older	
per	family	is	randomly	selected	to	self-report	responses	to	questions.		
The	sampling	plan	is	a	multistage	area	probability	design	that	permits	representative	
sampling	of	households	and	non-institutional	group	quarters	in	the	US.	Examples	of	persons	
excluded	from	this	study	include	patients	in	long-term	care	facilities,	persons	on	active	duty	
with	the	Armed	Forces,	persons	incarcerated	in	the	prison	system,	and	US	nationals	living	in	
foreign	countries.		
The	years	used	in	the	analysis;	2006,	2007,	2008,	and	2009	utilized	the	same	sampling	plan.	
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From	1987-2009	NHIS,	Participants	classified	as	eligible	for	mortality	follow	up	had	their	
sampling	weight	adjusted	to	account	for	those	ineligible	due	to	insufficient	identifying	data.	
This	new	weight	is	used	to	prevent	biased	mortality	estimates.	When	pooling	several	survey	
years	of	LMF	the	sample	weight	should	be	adjusted	by	dividing	each	weight	by	the	number	of	
years	being	pooled.	
	 NDI	Mortality	Files	
The	NCHS	has	linked	various	surveys	with	death	certificate	records	from	the	national	Death	
Index	(NDI).	The	primary	determination	of	mortality	is	based	upon	matching	survey	records	to	
the	NDI,	however	additional	sources	of	information	such	as	social	security	administration,	the	
Centers	for	Medicare	and	Medicaid	Services,	and	death	certificates	are	used	to	determine	the	
mortality	status	of	a	survey	participants.	Public	use	Linked	Mortality	Files	(LMF)	are	available	for	
1986-2009	NHIS	participants	with	mortality	follow	up	available	until	December	31,	2011.		The	
LMF	were	subjected	to	data	perturbation	techniques	to	reduce	the	risk	of	participant	re-
identification.	For	selected	entries	synthetic	data	were	substituted	for	the	actual	date	and	
underlying	cause	of	death,	however	comparative	analysis	of	cause	specific	mortality	across	
both	the	altered	and	unaltered	data	set	showed	similar	percentages	of	death	attributed	to	
leading	causes	of	death.		
	
	
Approval	
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This	thesis	utilized	secondary	public	use	data	and	did	not	require	Institutional	Review	
Board	(IRB)	approval.	The	NHIS	is	a	preapproved	data	source	with	exempt	status	determined	by	
the	Georgia	State	University	IRB	(Institutional	Review	Board	Policies).	
	
Inclusion	and	Exclusion	Criteria	
	 	Between	the	years	of	2006	and	2009	the	adult	sample	consisted	of	83,708.	Participants	
with	missing	responses	to	the	primary	questions	of	this	study	were	excluded	from	analysis.	The	
subpopulation	of	interest	were	white	and	African-American	women	with	breast	cancer,	thus	
the	sample	was	restricted	to	those	who	were	listed	as	Female	and	responded	yes	to	the	
questions	of	1)	Have	you	ever	been	told	by	a	doctor	that	you	had	cancer?	2)	What	kind	of	
cancer….Breast?.	Respondents	who	answered	no	to	either	question	were	excluded	from	
analysis	in	this	study.	The	resulting	sample	size	was	of	216	adults.		
	
Independent	Variables		
	 All	of	the	independent	variables	were	obtained	through	self-reported	survey	data	from	
the	2006-2009	NHIS	survey.	History	of	diabetes	is	operationalized	by	the	survey	question	“Have	
you	ever	been	told	you	have	diabetes?”	and	categorized	into	the	answers,	Yes,	No,	and	
Borderline.	For	the	sample	population,	this	is	derived	from	the	question	“If	female,	other	than	
during	pregnancy,	have	you	ever	been	told	by	a	doctor	or	health	professional	that	you	have	
diabetes	or	sugar	diabetes?”.	Age	first	diagnosed	with	diagnosed	with	diabetes	is	a	continuous	
variable.		Body	Mass	Index	(BMI)	was	determined		from	self-report	and	classified	into	4	
categories,	≤	18.5	=	underweight,	<18.5	BMI	≤	24.9	=	normal	weight,	24.9	<	BMI	≤	29.9	=	
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overweight,	and	overweight	≥	30.0.		Diabetic	medications	were	assessed	through	two	questions	
1)	“Are	you	now	taking	insulin?”	and	2)	“Are	you	now	taking	diabetic	pills	to	lower	your	blood	
sugar?	These	are	sometimes	called	oral	agents	or	oral	hypoglycemic	agents.”.	Age	was	
abstracted	from	the	continuous	variable	Age_P	in	the	NHIS	questionnaire	and	subsequently	
classified	into	3	categories,	18-34,	35-64,	and	65+.			
Pre-existing	diabetes	was	derived	from	the	two	variables,	“Age	first	diagnosed	with	breast	
cancer”	and	“Age	first	diagnosed	with	diabetes”.	Pre-existing	diabetes	was	classified	into	two	
categories,	Yes	(where	age	first	diagnosed	with	diabetes	<	age	first	diagnosed	with	breast	
cancer)	and	No	(where	age	first	diagnosed	with	diabetes	≥	age	first	diagnosed	with	breast	
cancer).	Years	of	diabetes	prior	to	cancer	diagnosis	was	abstracted	from	two	questions	in	the	
NHIS	questionnaire;	“Age	first	diagnosed	with	diabetes”	and	“Age	first	diagnosed	with	breast	
cancer.	Age	first	diagnosed	with	diabetes	was	subtracted	from	age	first	diagnosed	with	breast	
cancer.	The	resulting	integer	was	then	classified	into	four	categories;	where	the	equation	
resulted	in	a	negative	integer	the	category	was	“Developed	After”,	where	the	equation	resulted	
in	a	positive	integer,	the	results	were	classified	into	<	5	years,	5-10	years,	and	>	10	years.		
Age	first	diagnosed	with	cancer	is	a	continuous	variable	derived	from	the	survey	question	“How	
old	were	you	when	cancer	was	first	diagnosed?”	among	respondents	who	replied	yes	to	having	
been	diagnosed	with	breast	cancer.		
	
Dependent	Variables	
This	study	has	two	dependent	variables.	The	first	variable	assessed	is	history	of	diabetes	
is	operationalized	by	the	survey	question	“Have	you	ever	been	told	you	have	diabetes?”	and	
		 32	
categorized	into	the	answers,	Yes,	No,	and	Borderline.	For	the	sample	population,	this	is	
derived	from	the	question	“If	female,	other	than	during	pregnancy,	have	you	ever	been	told	by	
a	doctor	or	health	professional	that	you	have	diabetes	or	sugar	diabetes?”.	(	I	think	you	defined	
it	earlier,	so	consider	removing	the	earlier	one	The	second	variable	assessed	is	the	time	until	
the	final	mortality	status,	this	is	operationalized	by	the	final	mortality	status	obtained	from	the	
NDI	mortality	file.	The	final	variable	being	assessed	is	the	rate	of	death	due	to	breast	cancer	
specifically	and	all-causes	in	the	sample.	This	is	operationalized	by	the	leading	cause	of	death	
obtained	from	the	NDI	mortality	file.		
	
Data	Analysis	
	 All	analyses	for	this	study	were	conducted	using	Statistical	Analysis	Software	System	9.4	
(SAS	9.4).	Analysis	accounted	for	survey	design	by	the	incorporation	of	the	mortality	adjusted	
survey	weight	divided	by	4	to	account	for	pooled	variance	of	the	4	years	aggregated	into	the	
study	population.		
	 Descriptive	statistics	were	used	to	illustrate	characteristics	that	are	risk	factors	for	the	
development	of	breast	cancer	and	the	development	of	T2DM.	Frequency	distributions	were	
used	to	identify	the	proportion	of	NHIS	respondents	from	2006,	2007,	2008,	and	2009	who	
were	of	each	race	(African-American	and	White),	who	were	diagnosed	with	diabetes	and	who	
were	diagnosed	with	breast	cancer.	Additionally,	frequency	distributions	for	years	of	diabetes	
prior	to	cancer	diagnosis	and	leading	cause	of	death	among	breast	cancer	patients	were	
reported.	Chi-Square	tests	were	conducted	on	the	categorical	variables	and	t-tests	were	
		 33	
conducted	on	the	continuous	variables	for	differences	between	the	two	racial/ethnic	groups	
being	analyzed.		
	 Using	the	PHREG	procedure	in	SAS	9.4,	Cox	proportional	hazard	regression	analysis	was	
used	to	produce	two	models	that	estimate	the	hazard	ratio	and	respective	95%	confidence	
intervals	for	both	1)	all-cause	mortality	and	2)	breast	cancer	specific	mortality	for	each	race	
adjusted	for	the	independent	variables	of	interest.	In	each	model,	age	category,	insulin	
medication,	diabetic	pill	medication,	years	since	diagnosed	with	cancer,	BMI	category,	pre-
existing	diabetes,	and	years	of	diabetes	prior	to	cancer	diagnosis	were	the	included	variables.	
Risk	factors	were	selected	based	on	identification	in	the	literatures	as	contributors	towards	
mortality	in	breast	cancer	patients	and	availability	in	the	NHIS	questionnaire.	Un-adjusted	
univariate	and	adjusted	multivariate	models	were	produced.	P-values	of	0.05	or	less	and	
appropriate	95%	confidence	intervals	were	considered	statistically	significant.		
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Chapter	IV	
Results	
	
Inclusion	of	Cases	for	analysis	
	 	
Table	4.1:	Included	Cases	
Female	Breast	Cancer	Cases	Abstracted	from	NHIS	2006-2009	
(n=47,046)	
	 Unweighted	 Weighted	
NHIS	Total	Adult	Population	 83,708	 92,702,566	
NHIS	Population	of	Adult	Women	 47,046	 51,063,587	
NHIS	Population	of	Adult	Women	with	Diabetes	 4,289	 4,444,373	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	 1,318	 1,508,231	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	
and	Diabetes		
216	 234,165	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	
and	Diabetes	who	are	deceased		
30	 39,185	
	
	
Table	4.2:	Missing	Responses	
Female	Breast	Cancer	Cases	Abstracted	from	NHIS	2006-2009	
Frequency	Missing	
	 Unweighted	 Weighted	
NHIS	Total	Adult	Population	 13,472	 9,485,622	
NHIS	Population	of	Adult	Women	 7,269	 4,909,590	
NHIS	Population	of	Adult	Women	with	Diabetes	 630	 422,686	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	 113	 85,935	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	
and	Diabetes		
21	 15,181	
NHIS	Population	of	Adult	Women	with	Breast	Cancer	
and	Diabetes	who	are	deceased		
2	 1,749	
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Descriptive	Statistics	
	
Table	4.3	Adult	Women	in	the	U.S.	(2006-2009)	
	 White	(n=43,420,000)	 African-American/Black	
(n=7,643,674)		
p-value	
Age	 	 	 	
	 50.07	 44.86	 <0.0001	
Age	Category	 	 	 	
			18-34	
			35-65	
			65+	
10,900,000	(25.11%)		
21,780,000	(50.17%)	
10,730,000	(24.72%)	
2,651,621	(34.67%)	
3,733,633	(48.82%)		
1,263,017	(16.51%)	
<0.0001	
BMI	 	 	 	
	 26.86	 29.67	 <0.0001	
BMI	Category	 	 	 	
			Underweight	
			Normal	
			Overweight	
			Obese	
1,059,133	(2.44%)	
18,020,000	(41.50%)	
11,550,000	(26.61%)	
12,790,000(29.45%)	
20,198	(1.57%)	
1,990,378	(26.02%)	
2,127,757	(27.82%)	
3,409,939	(44.58%)	
<0.0001	
Diabetes	 	 	 	
			Yes	
			Borderline	
			No	
3,475,210	(8.10%)	
465,577	(1.07%)	
39,450,000	(90.92%)	
969,163	(12.68%)	
99,517	(1.30%)	
6,574,994	(86.02%)	
<0.0001	
Cancer	 	 	 	
			Yes	
			No	
4,865,083	(11.21%)	
38,510,000e7	(88.69%)	
357,537	(4.67%)	
7,286,716	(95.27%)	
<0.0001	
Breast	Cancer	 	 	 	
			Yes	
			No	
1,378,918	(3.18%)	
42,040,000	(96.82%)	
129,312	(1.69%)	
7,518,958	(98.31%)	
<0.0001	
	
Table	4.3	displays	the	characteristics	of	the	study	population	categorized	by	the	two	
racial/ethnic	groups	of	interest.		
The	mean	age	of	white	women	was	50.07	years,	compared	to	44.86	for	African-
American/Black	women.	The	breakdown	of	the	age	categories	reflected	this	trend	of	a	younger	
African-American/Black	population.	The	white	population	was	composed	of	25.11%	18-34	year	
olds,	50.17%	35-64	year	olds,	and	24.72%	aged	65+,	compared	to	34.67%,	48.82%,	and	16.51%	
respectively	for	the	black	population.	The	mean	BMI	for	white	women	was	26.86	compared	to	
29.67for	African-American/Black	women.	2.44%	of	white	women	were	classified	as	
underweight,	41.50%	as	normal	weight,	26.62%	as	overweight,	and	29.4%	as	obese.	
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Comparatively,	1.57%	of	African-American/Black	women	were	classified	as	underweight,	
26.02%	as	normal	weight,	27.82%	as	overweight,	and	44.58%	as	obese.	8.10%	of	white	women	
reported	having	diabetes,	1.07%	as	borderline	diabetic,	and	90.92%	as	not	having	diabetes.	
Comparatively,	12.68%	of	African-America/Black	women	reported	having	diabetes,	1.30%	as	
borderline	diabetic,	and	86.02%	as	not	having	diabetes.	11.21%	of	white	women	reported	
having	cancer	while	88.69%	reported	not	having	cancer.	4.67%	of	African-American/Black	
women	reported	having	cancer	while	95.27%	reported	not	having	any	type	of	cancer.	3.18%	of	
White	women	reporting	having	breast	cancer	and	96.82%	reported	not	having	breast	cancer.	
1.69%	of	black	women	reported	having	breast	cancer	while	98.31%	did	not	report	having	breast	
cancer.	Differences	between	all	characteristics	were	significant	across	the	two	racial/ethnic	
groups	at	the	p=0.05	level.	
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Table	4.4	Diabetic	Adult	Women	in	the	U.S.	(2006-2009)	
	 White	(n=3475210)	 African-America/Black	
(n=969163)	
P-value	
Age	 	 	 	
	 62.35	 59.57	 <0.0001	
Age	Category	 	 	 	
			18-34	
			35-64	
			65+	
144250	(4.15%)	
1714693	(49.34%)	
1616268	(46.51%)	
76564	(7.90%)	
491739	(50.74%)	
400861	(41.36%)	
<0.0001	
Age	Diagnosed	with	
Diabetes	
	 	 	
	 49.79	
	
46.08	 <0.0001	
BMI	 	 	 	
	 32.00	 33.13	 <0.0001	
BMI	Category	 	 	 	
			Underweight	
			Normal	
			Overweight	
			Obese	
21930	(0.63%)	
566530	(16.30%)	
916071	(26.36%)	
1970679	(56.71%)	
7386	(0.76%)	
119206	(12.30%)	
230992	(23.83%)	
611579	(63.10%)	
<0.0001	
Taking	Insulin	 	 	 	
			Yes	
			No	
916434	(26.40%)	
2555270	(73.60%)	
298111	(30.81%)	
669401	(69.19%)	
<0.0001	
Taking	Diabetic	Pills	 	 	 	
			Yes	
			No	
2434499	(70.10%)	
1038383	(29.90%)	
715931	(74.00%)	
251581	(26.00%)	
<0.0001	
Cancer	 	 	 	
			Yes	
			No	
638387	(18.37%)	
2833496	(81.53%)	
91796	(9.47%)	
877367	(90.53%)	
<0.0001	
Breast	Cancer	 	 	 	
			Yes	
			No	
191231	(5.50%)	
3283979	(94.50%)	
42934	(4.43%)	
926230	(95.57%)	
<0.0001	
	
Table	4.4	displays	the	prevalence	of	characteristics	of	the	population	of	US	women	with	
diabetes	categorized	by	the	two	racial/ethnic	groups	of	interest.		
The	mean	age	of	white	women	in	this	group	was	62.35	while	the	mean	age	of	African-
American/Black	women	was	59.57.		4.15%	of	Adult	white	women	with	diabetes	in	the	US	were	
estimated	to	be	in	the	18-34	years	of	age	group,	49.34%	in	the	35-64	years	of	age	group,	and	
46.51%	in	the	65+	years	of	age	group.	7.90%	of	Adult	African-American/Black	women	with	
diabetes	in	the	US	were	estimated	to	be	in	the	18-34	years	of	age	group,	50.74%	in	the	35-64	
years	of	age	group,	and	41.36%	in	the	65+	years	of	age	group.	The	mean	age	for	diagnosis	with	
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diabetes	for	white	women	was	estimated	to	be	49.79.	Comparatively,	the	mean	age	of	
diagnosis	with	diabetes	for	African-American/Black	women	was	46.08.	The	mean	BMI	of	white	
women	with	diabetes	was	32.00	compared	to	33.13	for	African-American/Black	women	with	
diabetes.	0.63%	of	white	women	with	diabetes	were	classified	as	underweight,	16.30%	as	
normal	weight,	26.36%	as	overweight,	and	56.71%	as	obese.	Comparatively,	0.76%	of	African-
American/Black	women	were	classified	as	underweight,	12.30%	as	normal	weight,	23.83%	as	
overweight,	and	63.10%	as	obese.	26.40%	of	white	women	with	diabetes	reported	taking	
insulin	while	73.60%	reported	not	taking	insulin.	Comparatively,	30.81%	of	African-
American/Black	women	reported	taking	insulin	while	69.19%	reported	not	taking	insulin.	
70.10%	of	white	women	with	diabetes	reported	taking	diabetic	pills	while	29.90%	reported	not	
taking	diabetic	pills.	Comparatively,	74%	of	African-American/Black	women	with	diabetes	
reported	taking	diabetic	pills	and	26%	reported	not	taking	diabetic	pills.	18.37%	of	white	
women	with	diabetes	reported	having	cancer	of	some	type,	while	9.47%	of	black	women	with	
diabetes	reported	having	cancer.	5.50%	of	white	women	with	diabetes	reported	having	breast	
cancer,	while	4.43%	of	African-American/Black	women	with	diabetes	reported	having	breast	
cancer.		Differences	between	all	characteristics	were	significant	across	the	two	racial/ethnic	
groups	at	the	p=0.05	level.		
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Table	4.5	Adult	Women	with	Breast	Cancer	in	the	U.S.	(2006-2009)	
	 White	(n=	1378918)	 African-America/Black	
(n=129312)	
P-Value	
Age	 	 	 	
	 67.73	 62.53	 <0.0001	
Age	Category	 	 	 	
			18-34	
			35-64	
			65+	
6222	(0.45%)	
539121	(39.10%)	
833575	(55.27%)	
3062	(2.37%)	
65143	(50.38%)	
61107	(47.26%)	
<0.0001	
Age	Diagnosed	with	
Breast	Cancer	
	 	 	
	 56.36	 50.42	 <0.0001	
BMI	 	 	 	
	 26.96	 29.83	 <0.0001	
BMI	Category	 	 	 	
			Underweight	
			Normal	
			Overweight	
			Obese	
27353	(1.98%)	
540715	(39.21%)	
415554	(30.14%)	
726214	(28.67%)	
1361	(1.05%)	
33029	(25.54%)	
38399	(29.69%)	
56523	(43.71%)	
<0.0001	
Diabetes	 	 	 	
			Yes	
			Borderline	
			No	
191231	(13.87%)	
17309	(1.26%)	
1170378	(84.88%)	
42934	(33.20%)	
1707	(1.32%)	
84672	(65.48%)	
<0.0001	
	
Table	4.5	displays	the	prevalence	of	selected	characteristics	of	the	US	population	of	
women	with	breast	cancer	categorized	by	the	two	racial/ethnic	groups	of	interest.	
	The	mean	age	of	white	women	with	breast	cancer	was	estimated	to	be	67.73	compared	
to	a	mean	age	of	62.53	for	African-American/Black	women	with	breast	cancer.	0.45%	of	Adult	
white	women	with	breast	cancer	in	the	US	were	estimated	to	be	in	the	18-34	years	of	age	
group,	39.10%	in	the	35-64	years	of	age	group,	and	55.27%	in	the	65+	years	of	age	group.		
2.37%	of	Adult	African-American/Black	women	with	breast	cancer	in	the	US	were	estimated	to	
be	in	the	18-34	years	of	age	group,	50.38%	in	the	35-64	years	of	age	group,	and	47.26%	in	the	
65+	years	of	age	group.	The	mean	BMI	of	white	women	with	breast	cancer	was	26.96	compared	
to	29.83	for	African-American/Black	women	with	breast	cancer.	1.98%	of	white	women	with	
breast	cancer	were	classified	as	underweight,	39.21%	as	normal	weight,	30.14%	as	overweight,	
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and	28.67%	as	obese.	Comparatively,	1.05%	of	African-American/Black	women	with	breast	
cancer	were	classified	as	underweight,	25.54%	as	normal	weight,	29.69%	as	overweight,	and	
43.71%	as	obese.	13.87%	of	white	women	with	breast	cancer	reported	having	diabetes,	1.26%	
as	borderline	diabetic,	and	84.88%	as	not	having	diabetes.	Comparatively,	33.20%	of	African-
American/Black	women	with	breast	cancer	reported	having	diabetes,	1.32%	as	borderline	
diabetic,	and	65.48%	as	not	having	diabetes.	Differences	between	all	characteristics	were	
significant	across	the	two	racial/ethnic	groups	at	the	p=0.05	level.	
Table	4.6	Non-Diabetic	Adult	Women	with	Breast	Cancer	in	the	U.S.	(2006-2009)	
	 White	 African-American/Black	 P-Value	
Age	 	 	 	
	 67.36	 60.71	 <0.0001	
Age	Category	 	 	 	
			18-34	
			35-65	
			65+	
15777	(0.75%)	
975603	(46.13%)	
1123342	(53.12%)	
6370	(4.22%)		
82708	(54.85%)	
61708	(40.92%)	
<0.0001	
Age	First	Diagnosed	with	
Breast	Cancer	
	 	 	
	 55.99	 50.60	 0.0024	
BMI	 	 	 	
	 26.23	 28.91	 <0.0001	
BMI	Category	 	 	 	
			Underweight	
			Normal	
			Overweight	
			Obese	
44312	(2.10%)	
897590	(42.44%)	
627357	(29.67%)	
545463	(25.79%)	
0	
44854	(29.75%)	
46930	(31.12%)	
59001	(39.13%)	
<0.0001	
Leading	Underlying	Cause	
of	Death	
	 	 	
			Heart	Disease	
			Malignant	
Neoplasms	
			Chronic	Lower-	
Respiratory	Diseases	
			Accidents	
			Cerebrovascular	
Diseases	
			Diabetes	
Alzheimer’s	
			Influenza	and	
pneumonia	
			Kidney	Disease	
			All	other	Causes	
12919	(9.30%)	
62902	(45.26%)	
	
6894	(4.96%)	
	
5537	(3.98%)	
6493	(4.67%)	
	
0	
4300	(3.09%)	
2714	(1.95%)	
	
1201	(0.86%)	
36019	(25.92%)	
1516	(17.05%)	
5433	(61.09%)	
	
0	
	
0	
0	
	
0	
0	
0	
	
0	
1945	(21.86%)	
<0.0001	
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Table	4.6	displays	the	prevalence	of	selected	characteristics	of	US	women	with	breast	
cancer	who	do	not	have	diabetes	categorized	by	the	two	racial/ethnic	groups	of	interest.	
	The	mean	age	of	white	women	with	breast	cancer	and	no	diabetes	was	estimated	to	be	
67.37	compared	to	a	mean	age	of	60.71	for	African-American/Black	women	with	breast	cancer	
and	diabetes.	0.75%	of	Adult	white	women	with	breast	cancer	and	no	diabetes	in	the	US	were	
estimated	to	be	in	the	18-34	years	of	age	group,	46.13%	in	the	35-64	years	of	age	group,	and	
53.12%	in	the	65+	years	of	age	group.	4.22%	of	Adult	African-American/Black	women	with	
breast	cancer	and	no	diabetes	in	the	US	were	estimated	to	be	in	the	18-34	years	of	age	group,	
54.85%	in	the	35-64	years	of	age	group,	and	40.92%	in	the	65+	years	of	age	group.	The	mean	
BMI	of	white	women	with	breast	cancer	and	no	diabetes	was	26.23	compared	to	28.91	for	
African-American/Black	women	with	breast	cancer	and	no	diabetes.	2.10%	of	white	women	
with	breast	cancer	and	no	diabetes	were	classified	as	underweight,	42.44%	as	normal	weight,	
26.67%	as	overweight,	and	25.79%	as	obese.	Comparatively,	0%	of	African-American/Black	
women	with	breast	cancer	and	no	diabetes	were	classified	as	underweight,	29.75%	as	normal	
weight,	31.12%	as	overweight,	and	39.13%	as	obese.	Of	White	women	with	breast	cancer	and	
no	diabetes	who	died	during	the	study	period,	heart	disease	was	the	leading	cause	of	death	for	
9.30%,	malignant	neoplasms	was	the	leading	cause	of	death	for	45.26%,	chronic	respiratory	
disease	was	the	leading	cause	of	death	for	4.96%,	accidents	were	the	leading	cause	for	3.98%,		
cerebrovascular	disease	was	the	leading	cause	for	4.67%,		diabetes	was	the	leading	cause	for	
0%,	Alzheimer’s	was	the	leading	cause	for	3.09%,	influenza	and	pneumonia	was	the	leading	
cause	for	1.95%,		kidney	disease	was	the	leading	cause	for	0.86%,	and	all	other	causes	
accounted	for	25.92%.	Comparatively,	of	African-American/Black	women	with	breast	cancer	
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and	no	diabetes	who	died	during	the	study	period,	heart	disease	was	the	leading	cause	of	death	
for	17.05%,	malignant	neoplasms	was	the	leading	cause	of	death	for	61.09%,	chronic	
respiratory	disease	was	the	leading	cause	of	death	for	0%,	accidents	were	the	leading	cause	for	
0%,		cerebrovascular	disease	was	the	leading	cause	for	0%,		diabetes	was	the	leading	cause	for	
0%,	Alzheimer’s	was	the	leading	cause	for	0%,	influenza	and	pneumonia	was	the	leading	cause	
for	0%,		kidney	disease	was	the	leading	cause	for	0%,	and	all	other	causes	accounted	for	
21.86%.	Differences	between	all	characteristics	were	significant	across	the	two	racial/ethnic	
groups	at	the	p=0.05	level.	
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Table	4.7	Diabetic	Adult	Women	with	Breast	Cancer	in	the	U.S.	(2006-2009)	
	 White	(n=331070)	 African-American/Black	
(n=63786)	
P-Value	
Mean	Age	 	 	 	
	 70.16	 66.46	 0.0543	
Age	Category	
			18-34	
			35-65	
			65+	
477(0.25%)	
52051	(27.22%)	
138704	(72.53%)	
0	
18227	(42.45%)	
24707	(57.55%)	
<0.0001	
Age	First	Diagnosed	with		
Breast	Cancer	
	 58.77	 50.41	 0.0019	
BMI	
	 30.92	 31.54	 0.6717	
BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
2174	(1.14%)	
41277	(21.58%)	
58127	(30.40%)	
89654	(46.88%)	
1361	(3.17%)	
7016	(16.34%)	
12604	(29.36%)	
21953	(51.13%)	
<0.0001	
Preexisting	Diabetes	 	 	 	
			Yes	
			No	
76140	(39.82%)	
115091	(60.18%)	
22428	(52.24%)	
20505	(47.76%)	
<0.0001	
Age	First	Diagnosed	with	Diabetes	 	 	 	
	 57.90	 47.95	 0.0009	
Years	of	Diabetes	Prior	to	Cancer	
Diagnosis	
	 	 	
	 -0.7681	 3.1687	 0.4500	
Years	of	Diabetes	Prior	to	Cancer		
Diagnosis	
			Developed	After	
			<	5	years	
			5-10	Years	
			>	10	Years	
	
100286	(52.44%)	
41327	(21.61%)	
16071	(8.40%)	
33547	(17.54%)	
16629	(38.73%)	
18227	(21.61%)	
6559	(15.28%)	
11518	(26.83%)	
<0.0001	
Taking	Insulin	
	
	 	 	
			Yes	
			No	
42802	(22.51%)	
147338	(77.49%)	
10901	(25.39%)	
32032	(74.61%)	
	<0.0001	
Taking	Diabetic	Pills	 	 	 	
			Yes	
			No	
140388	(73.41%)	
50843	(26.59%)	
34328	(79.96%)	
8606	(20.04%)	
<0.0001	
Leading	Underlying	Cause	of	Death	 	 	 	
	Heart	Disease	
			Malignant	Neoplasms	
			Chronic	Lower-	Respiratory	
Diseases	
			Accidents	
			Cerebrovascular	Diseases	
			Diabetes	
			Influenza	and	pneumonia	
			Kidney	Disease	
			All	other	Causes	
	
1089	(3.35%)	
12302	(37.81%)	
1916	(5.89%)	
	
1971	(6.06%)	
1859	(5.71%)	
3825	(11.76%)	
1509	(4.64%)	
2104	(6.47%)	
5963	(18.33%)	
0	
4062	(61.10%)	
621	(9.34%)	
	
0	
0	
667	(10.03%)	
0	
669	(10.07%)	
629	(9.46%)	
<0.0001	
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Table	4.7	displays	the	prevalence	of	selected	characteristics	of	US	women	with	both	
diabetes	and	breast	cancer	categorized	by	the	two	racial/ethnic	groups	of	interest.		
The	mean	age	of	white	women	with	breast	cancer	and	diabetes	was	estimated	to	be	
70.16	compared	to	a	mean	age	of	66.46	for	African-American/Black	women	with	breast	cancer	
and	diabetes.	0.25%	of	Adult	white	women	with	breast	cancer	and	diabetes	in	the	US	were	
estimated	to	be	in	the	18-34	years	of	age	group,	27.22%	in	the	35-64	years	of	age	group,	and	
72.53%	in	the	65+	years	of	age	group.	0%	of	Adult	African-American/Black	women	with	breast	
cancer	and	diabetes	in	the	US	were	estimated	to	be	in	the	18-34	years	of	age	group,	42.55%	in	
the	35-64	years	of	age	group,	and	57.55%	in	the	65+	years	of	age	group.	The	mean	BMI	of	white	
women	with	breast	cancer	and	diabetes	was	30.92	compared	to	31.54for	African-
American/Black	women	with	breast	cancer	and	diabetes.	1.14%	of	white	women	with	breast	
cancer	and	diabetes	were	classified	as	underweight,	21.58%	as	normal	weight,	30.40%	as	
overweight,	and	46.88%	as	obese.	Comparatively,	3.17%	of	African-American/Black	women	
with	breast	cancer	and	diabetes	were	classified	as	underweight,	16.34%	as	normal	weight,	
29.36%	as	overweight,	and	51.13%	as	obese.	39.82%	of	white	women	with	breast	cancer	and	
diabetes	had	pre-existing	diabetes,	compared	to	52.24%	of	African-American/Black	women.	
The	mean	age	for	diagnosis	with	diabetes	for	white	women	with	breast	cancer	was	estimated	
to	be	57.90,	compared	to	47.95	for	African-American/Black	women.	White	women	with	breast	
cancer	and	diabetes	developed	diabetes	on	average	0.7861	years	after	being	diagnosed	with	
breast	cancer.	Comparatively,	African-America/Black	women	with	breast	cancer	and	diabetes	
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developed	diabetes	3.1687	years	prior	to	being	diagnosed	with	breast	cancer.	52.44%	of	white	
women	with	diabetes	were	diagnosed	with	diabetes	after	breast	cancer	diagnosis,	21.61	
developed	diabetes	less	than	5	years	before	breast	cancer	diagnosis,	8.40%	developed	diabetes	
between	5	and	10	years	before	breast	cancer	diagnosis,	and	17.54%	more	than	10	years	before	
breast	cancer	diagnosis.	Comparatively,	38.73%	of	white	women	with	diabetes	were	diagnosed	
with	diabetes	after	breast	cancer	diagnosis,	21.61	developed	diabetes	less	than	5	years	before	
breast	cancer	diagnosis,	15.28%	developed	diabetes	between	5	and	10	years	before	breast	
cancer	diagnosis,	and	26.83%	more	than	10	years	before	breast	cancer	diagnosis.	22.51%	of	
white	women	with	breast	cancer	and	diabetes	reported	taking	insulin	while	77.49%	reported	
not	taking	insulin.	Comparatively,	25.39%	of	African-American/Black	women	with	breast	cancer	
and	diabetes	reported	taking	insulin	while	74.61%	reported	not	taking	insulin.	73.41%	of	white	
women	with	breast	cancer	and	diabetes	reported	taking	diabetic	pills	while	26.59%	reported	
not	taking	diabetic	pills.	Comparatively,	79.96%	of	African-American/Black	women	with	breast	
cancer	and	diabetes	reported	taking	diabetic	pills	and	20.04%	reported	not	taking	diabetic	pills.	
Of	White	women	with	breast	cancer	and	diabetes	who	died	during	the	study	period,	heart	
disease	was	the	leading	cause	of	death	for	3.35%,	malignant	neoplasms	was	the	leading	cause	
of	death	for	37.81%,	chronic	respiratory	disease	was	the	leading	cause	of	death	for	5.89%,	
accidents	were	the	leading	cause	for	6.06%,		cerebrovascular	disease	was	the	leading	cause	for	
5.71%,		diabetes	was	the	leading	cause	for	11.76%,	influenza	and	pneumonia	was	the	lead	
cause	for	4.64%,		kidney	disease	was	the	leading	cause	for	6.47%,	and	all	other	causes	
accounted	for	18.33%.		Comparatively,	of	African-American/Black	women	with	breast	cancer	
and	diabetes	who	died	during	the	study	period,	heart	disease	was	the	leading	cause	of	death	
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for	0%,	malignant	neoplasms	was	the	leading	cause	of	death	for	61.10%,	chronic	respiratory	
disease	was	the	leading	cause	of	death	for	9.34%,	accidents	were	the	leading	cause	for	0%,		
cerebrovascular	disease	was	the	leading	cause	for	0%,		diabetes	was	the	leading	cause	for	
10.03%,	influenza	and	pneumonia	was	the	leading	cause	for	0%,		kidney	disease	was	the	leading	
cause	for	10.07%,	and	all	other	causes	accounted	for	9.46%.	With	the	exception	of	mean	age,	
mean	BMI,	and	mean	years	of	diabetes	prior	to	breast	cancer	diagnosis,	differences	between	all	
characteristics	were	significant	across	the	two	racial/ethnic	groups	at	the	p=0.05	level.	
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Cox	Proportional	Hazard	Models	
	
Table	4.8:	Unadjusted	Univariate	All-Cause	Mortality		
Model		 Variable	 Hazard	Ratio	 95%	Confidence	Interval	
Model	1:	Women	with	Breast	
Cancer	
	 	 	
	 Age	Category	
			18-34	
			35-64	
			65+	
	
-----	
2.741	
2.357	
	
----	
(2.544-2.954)	
(2.190-2.536)	
	 Race	
			White	
			African-American/Black	
	
----	
1.217	
	
----	
(1.191-1.243)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0.944	
----	
0.761	
1.094	
	
(0.909-0.979)	
---	
(0.749-0.773)	
(1.077-1.111)	
	 Ever	Been	Diagnosed	with	
Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.504	
1.354	
---	
	
	
(1.485-1.524)	
(1.274-1.438)	
---	
	 Years	of	Diabetes	Prior	to	
Cancer	Diagnosis	
			Developed	After	
			<	5	years	
			5-10	years	
			10+	years	
	
	
	
---	
1.551	
1.808	
1.922	
	
	
	
---	
(1.511-1.591)	
(1.756-1.862)	
(1.883-1.961)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
0.908	
---	
	
(0.893-0.923)	
Model	2:	Women	with	Breast	
Cancer	and	Diabetes		
	 	 	
	 Age	Category	
			18-34	
			35-64	
			65+	
	
--	
1.215	
.	
	
---	
(1.184-1.247)	
.	
	 Race	
			White	
			African-American/Black	
	
---	
1.226	
	
---	
(1.194-1.259)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
7.299	
---	
1.097	
1.346	
	
(6.934-7.682)	
---	
(1.066-1.128)	
(1.314-1.379)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
1.309	
---	
	
(1.282-1.336)	
----	
	 Years	of	Diabetes	Prior	to	
Cancer	Diagnosis	
			Developed	After	
			<	5	years	
			5-10	years	
			10+	years	
	
	
	
---	
1.257	
1.398	
1.543	
	
	
	
---	
(1.221-1.294)	
(1.353-1.445)	
(1.504-1.582)	
	 Taking	Insulin	
			Yes	
			No	
	
1.220	
---	
	
(1.193-1.247)	
---	
	 Taking	Diabetic	Pills	
			Yes	
			No	
	
0.756	
---	
	
(0.740-0.772)	
---	
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Table	4.8	displays	the	unadjusted	hazard	ratios	of	all-cause	mortality	and	accompanying	
95%	confidence	intervals	for	specified	covariates	of	two	cox	proportional	hazards	models,	one	
conducted	using	all	women	with	breast	cancer,	and	the	other	using	only	women	with	both	
breast	cancer	and	diabetes.	
	Model	1	was	conducted	using	all	women	with	breast	cancer.	The	age	category	of	35-64	
was	associated	with	a	2.741	(2.544-2.954	95%	CI)	times	higher	hazard	of	mortality	than	the	18-
34	age	group.	Similarly,	the	age	category	of	65+	was	associated	with	a	2.357	(2.190-2.536	95%	
CI)	times	higher	hazard	of	mortality	than	the	18-34	age	group.	The	racial	classification	of	
African-American/Black	was	associated	with	a	1.217	(1.191-1.243	95%	CI)	times	higher	hazard	
of	mortality	than	the	racial	classification	of	White.	The	BMI	categories	of	underweight,	
overweight,	and	obese,	were	associated	with	a	0.944(0.909-0.979	95%	CI)	times	lower,	0.761	
(0.749-0.773	95%	CI)	times	lower,	and	1.094(1.077-1.111	95%	CI)	times	higher	hazard	of	
mortality	than	the	BMI	category	of	normal	weight	respectively.	Those	who	reported	being	
diagnosed	with	diabetes	and	those	who	reported	being	diagnosed	with	borderline	diabetes	
were	associated	with	a	1.504	(1.485-1.524	95%	CI)	and	1.354	(1.274-1.438	95%	CI)	respectively,	
times	higher	hazard	of	mortality	than	those	without	diabetes.		Having	diabetes	for	up	to	5	years	
prior	to	cancer	diagnosis	was	associated	with	a	1.551	(1.511-1.591	95%	CI)	times	higher	hazard	
of	mortality	than	developing	diabetes	after	breast	cancer	diagnosis.		Having	diabetes	for	5-10	
years,	and	10+	years	prior	to	diagnosis	with	breast	cancer	were	associated	with	1.808	(1.756-
1.862	95%	CI)	and	1.922	(1.883-1.961	95%	CI)	respectively	times	higher	hazard	of	mortality	than	
diabetes	developed	after	breast	cancer	diagnosis.	Pre-existing	diabetes	was	associated	with	a	
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0.908	(0.893-0.923	95%	CI)	times	lower	hazard	of	mortality	than	diabetes	developed	after	
cancer	diagnosis.		
Model	2	was	conducted	using	only	women	with	both	breast	cancer	and	diabetes.	The	
age	category	of	35-64	was	associated	with	a	1.215	(1.184-1.247	95%	CI)	times	higher	hazard	of	
mortality	than	the	18-34	age	group.	Due	to	a	lack	of	sufficient	data,	no	hazard	ratio	was	
produced	for	the	65+	age	group.	The	racial	classification	of	African-American/Black	was	
associated	with	a	1.215	(1.184-1.247	95%	CI)	times	higher	hazard	of	mortality	than	the	racial	
classification	of	White.		The	BMI	categories	of	underweight,	overweight,	and	obese,	were	
associated	with	a	7.299	(6.934-7.682	95%	CI)	times	higher,	1.097	(1.066-1.128	95%	CI)	times	
lower,	and	1.346	(1.314-1.379	95%	CI)	times	higher	hazard	of	mortality	than	the	BMI	category	
of	normal	weight	respectively.	Pre-existing	diabetes	was	associated	with	a	1.309	(1.282-1.336	
95%	CI)	times	higher	hazard	of	mortality	than	diabetes	developed	after	cancer	diagnosis.	
Having	diabetes	for	up	to	5	years	prior	to	cancer	diagnosis	was	associated	with	a	1.257	(1.221-
1.294	95%	CI)	times	higher	hazard	of	mortality	than	developing	diabetes	after	breast	cancer	
diagnosis.		Having	diabetes	for	5-10	years,	and	10+	years	prior	to	diagnosis	with	breast	cancer	
were	associated	with	1.398	(1.353-1.445	95%	CI)	and	1.543	(1.504-1.582	95%	CI)	respectively	
times	higher	hazard	of	mortality	than	diabetes	developed	after	breast	cancer	diagnosis.	Taking	
Insulin	was	associated	with	a	1.220	(1.193-1.247	95%	CI)	times	increased	hazard	of	mortality	
than	not	taking	insulin.	Taking	diabetic	pills	was	associated	with	a	0.756	(0.740-0.772	95%	CI)	
times	lower	hazard	of	mortality	than	not	taking	diabetic	pills.		
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Table	4.9:	Adjusted	Multivariate	All-Cause	Mortality		
Model	 Variable		 Hazard	Ratio	 95%	Confidence	Interval	
Model	1:	Women	with	
Breast	Cancer		
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
------	
2.530	
2.297	
	
-------	
(2.895-3.384)	
(2.279-2.644)	
	 Race	
			White	
			African-American/Black	
	
-------	
1.102	
	
------	
(1.076-1.130)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
1.025	
--------	
0.800	
0.989	
	
(0.987-1.065)	
------------------	
(0.787-0.813)	
(0.972-1.006)	
	 Ever	Been	Diagnosed	With	
Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.603	
1.154	
--------	
	
	
(1.577-1.630)	
(1.083-1.230)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
1.329	
--------	
	
(1.301-1.358)	
Model	2:	Women	with	
Diabetes	and	Breast	Cancer	
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
----------	
1.645	
What	happened	here?	
	
---	
(1.551-1.744)	
.	
	 Race	
			White	
			African-American/Black	
	
-------	
0.741	
	
---	
(0.711-0.773)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
12.281	
-------	
1.410	
1.353	
	
(11.506-13.107)	
---	
(1.361-1.461)	
(1.302-1.406)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
1.157	
------	
	
(1.109-1.206)	
	 Years	of	Diabetes	Prior	to	
Cancer	Diagnosis	
			Developed	After	
			<	5	years	
			5-10	years	
			10+	years	
	
	
----	
0.895	
1.378	
1.184	
	
	
---	
(0.848-0.945)	
(1.305-1.455)	
(1.128-1.242)	
	 Taking	Insulin	
			Yes	
			No	
	
1.140	
---	
	
(1.094-1.188)	
---	
	 Taking	Diabetic	Pills	
			Yes	
			No	
	
0.889	
---	
	
(0.860-0.919)	
---	
	
Table	4.9	displays	the	adjusted	hazard	ratios	of	all-cause	mortality	and	accompanying	
95%	confidence	intervals	for	specified	covariates	of	two	cox	proportional	hazards	models,	one	
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conducted	using	all	women	with	breast	cancer,	and	the	other	using	only	women	with	both	
breast	cancer	and	diabetes.	
	 Model	1	was	conducted	using	all	women	with	breast	cancer.	Controlling	for	all	
other	co-variates,	the	age	category	of	35-64	was	associated	with	a	2.530	(2.344-2.731	95%	CI)	
times	higher	hazard	of	mortality	than	the	18-34	age	group.	Similarly,	the	age	category	of	65+	
was	associated	with	a	2.297	(2.133-2.474	95%	CI)	times	higher	hazard	of	mortality	than	the	18-
34	age	group.	Controlling	for	all	other	co-variates,	the	racial	classification	of	African-
American/Black	was	associated	with	a	1.102	(1.017-1.172	95%	CI)	times	higher	hazard	of	
mortality	than	the	racial	classification	of	White.		Controlling	for	all	other	co-variates,	the	BMI	
categories	of	underweight,	overweight,	and	obese,	were	associated	with	a	1.025	(0.987-1.065	
95%	CI)	times	higher,	0.800	(0.787-0.813	95%	CI)	times	lower,	and	0.989(0.972-1.006	95%	CI)	
times	lower	hazard	of	mortality	than	the	BMI	category	of	normal	weight	respectively.	
Controlling	for	all	other	co-variates,	those	who	reported	being	diagnosed	with	diabetes	and	
those	who	reported	being	diagnosed	with	borderline	diabetes	were	associated	with	a	1.603	
(1.577-1.630	95%	CI)	and	1.154	(1.083-1.230	95%	CI)	respectively,	times	higher	hazard	of	
mortality	than	those	without	diabetes.	Controlling	for	all	other	co-variates,	pre-existing	
diabetes	was	associated	with	a	1.329	(1.301-1.358	95%	CI)	times	higher	hazard	of	mortality	
than	diabetes	developed	after	cancer	diagnosis.		
Model	2	was	conducted	using	only	women	with	both	breast	cancer	and	diabetes.	
Controlling	for	all	other	covariates,	the	age	category	of	35-64	was	associated	with	a	1.215	
(1.184-1.247	95%	CI)	times	higher	hazard	of	mortality	than	the	18-34	age	group.	Due	to	a	lack	
of	sufficient	data,	no	hazard	ratio	was	produced	for	the	65+	age	group.	Controlling	for	all	other	
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co-variates,	the	racial	classification	of	African-American/Black	was	associated	with	a	0.741	
(0.711-0.773	95%	CI)	times	lower	hazard	of	mortality	than	the	racial	classification	of	White.	
Controlling	for	all	other	co-variates,	the	BMI	categories	of	underweight,	overweight,	and	obese,	
were	associated	with	a	12.281	(11.56-13.107	95%	CI)	times	higher,	1.410	(1.361-1.461	95%	CI)	
times	higher,	and	1.353	(1.301-1.406	95%	CI)	times	higher	hazard	of	mortality	than	the	BMI	
category	of	normal	weight	respectively.	Controlling	for	all	other	co-variates,	pre-existing	
diabetes	was	associated	with	a	1.157	(1.09-1.206	95%	CI)	times	higher	hazard	of	mortality	than	
diabetes	developed	after	cancer	diagnosis.	Controlling	for	all	other	co-variates,	having	diabetes	
for	up	to	5	years	prior	to	cancer	diagnosis	was	associated	with	a	0.895(0.848-0.945	95%	CI)	
times	lower	hazard	of	mortality	than	developing	diabetes	after	breast	cancer	diagnosis.		Having	
diabetes	for	5-10	years,	and	10+	years	prior	to	diagnosis	with	breast	cancer	were	associated	
with	1.378	(1.305-1.455	95%	CI)	and	1.184	(1.128-1.242	95%	CI)	respectively	times	higher	
hazard	of	mortality	than	diabetes	developed	after	breast	cancer	diagnosis.	Controlling	for	all	
other	co-variates,	taking	Insulin	was	associated	with	a	1.140	(1.084-1.188	95%	CI)	times	higher	
hazard	of	mortality	than	not	taking	insulin.	Controlling	for	all	other	co-variates,	taking	diabetic	
pills	was	associated	with	a	0.889	(0.860-0.919	95%	CI)	times	lower	hazard	of	mortality	than	not	
taking	diabetic	pills.		
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Table	4.10:	Unadjusted	Univariate	Breast	Cancer	Specific	Mortality	
Model	 Variable		 Hazard	Ratio	 95%	Confidence	Interval	
Model	1:	Women	with	
Breast	Cancer			
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
---	
1.728	
0.678	
	
--	
(1.602-1.864)	
(0.630-0.731)	
	 Race	
			White	
			African-American/Black	
	
---	
1.990	
	
---	
(1.935-2.046)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0	
---	
0.788	
1.180	
	
(0-7.934e11)	
---	
(0.769-0.87)	
(1.152-1.209)	
	 Ever	Been	Diagnosed	
With	Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.475	
0	
--------	
	
	
(1.445-1.505)	
(0-1.88e11)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
0.935	
--------	
	
(0.910-0.961)	
Model	2:	Women	with	
Diabetes	and	Breast	
Cancer	
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
------	
2.326	
.	
	
-------	
(2.251-2.404)	
.	
	 Race	
			White	
			African-American/Black	
	
-------	
1.879	
	
------	
(1.813-1.947)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0	
--------	
0.630	
0.913	
	
(0-2.162e20)	
------------------	
(0.602-0.658)	
(0.882-0.945)	
	 Years	of	Diabetes	Prior	to	
Cancer	Diagnosis	
			Developed	After	
			<	5	years	
			5-10	years	
			10+	years	
	
	
----	
1.307	
2.652	
0.972	
	
	
---	
(1.251-1.367)	
(2.545-2.763)	
(0.929-1.017)	
	 Taking	Insulin	
			Yes	
			No	
	
0.578	
---	
	
(0.554-0.603)	
---	
	 Taking	Diabetic	Pills	
			Yes	
			No	
	
0.706	
---	
	
(0.684-0.730)	
---	
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	 Table	4.10	displays	the	unadjusted	hazard	ratios	of	breast	cancer	specific	mortality	and	
accompanying	95%	confidence	intervals	for	specified	covariates	of	two	cox	proportional	
hazards	models,	one	conducted	using	all	women	with	breast	cancer,	and	the	other	using	only	
women	with	both	breast	cancer	and	diabetes.	
Model	1	was	conducted	using	all	women	with	breast	cancer.	The	age	category	of	35-64	
was	associated	with	a	1.728	(1.602-1.864	95%	CI)	times	higher	hazard	of	breast	cancer	specific	
mortality	than	the	18-34	age	group.	The	age	category	of	65+	was	associated	with	a	0.678	
(0.630-0.731	95%	CI)	times	lower	hazard	of	breast	cancer	specific	mortality	than	the	18-34	age	
group.	The	racial	classification	of	African-American/Black	was	associated	with	a	1.990	(1.935-
2.046	95%	CI)	times	higher	hazard	of	breast	cancer	specific	mortality	than	the	racial	
classification	of	White.	The	BMI	categories	of	underweight,	overweight,	and	obese,	were	
associated	with	a	0	(0-7.934e11	95%	CI)	times,	0.788	(0.769-0.870	95%	CI)	times	lower,	and	
1.180	(1.152-1.209	95%	CI)	times	higher	hazard	of	breast	cancer	specific	mortality	than	the	BMI	
category	of	normal	weight	respectively.	Those	who	reported	being	diagnosed	with	diabetes	and	
those	who	reported	being	diagnosed	with	borderline	diabetes	were	associated	with	a	1.475	
(1.445-1.505	95%	CI)	and	0	(0-1.88e1195%	CI)	respectively,	times	higher	hazard	of	breast	
cancer	specific	mortality	than	those	without	diabetes.	Pre-existing	diabetes	was	associated	with	
a	0.935	(0.910-0.961	95%	CI)	time	lower	hazard	of	breast	cancer	specific	mortality	than	
diabetes	developed	after	breast	cancer	diagnosis.		
Model	2	was	conducted	using	only	women	with	both	breast	cancer	and	diabetes.	The	
age	category	of	35-64	was	associated	with	a	2.326	(2.251-2.404	95%	CI)	times	higher	hazard	of	
breast	cancer	specific	mortality	than	the	18-34	age	group.	Due	to	a	lack	of	sufficient	data,	no	
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hazard	ratio	was	produced	for	the	65+	age	group.	The	racial	classification	of	African-
American/Black	was	associated	with	a	1.879	(1.813-1.947	95%	CI)	times	higher	hazard	of	breast	
cancer	specific	mortality	than	the	racial	classification	of	White.	The	BMI	categories	of	
underweight,	overweight,	and	obese,	were	associated	with	a	0	(0-2.162e20	95%	CI)	times,	
0.630	(0.602-0.658	95%	CI)	times	lower,	and	0.913	(0.882-0.945	95%	CI)	times	higher	hazard	of	
breast	cancer	specific	mortality	than	the	BMI	category	of	normal	weight	respectively.	Having	
diabetes	for	up	to	5	years	prior	to	cancer	diagnosis	was	associated	with	a	1.307(1.251-1.367	
95%	CI)	times	lower	hazard	of	mortality	than	developing	diabetes	after	breast	cancer	diagnosis.		
Having	diabetes	for	5-10	years,	and	10+	years	prior	to	diagnosis	with	breast	cancer	were	
associated	with	2.652	(2.545-2.763	95%	CI)	times	higher	and	0.972	(1.128-1.242	95%	CI)	times	
lower	hazard	of	breast	cancer	specific	mortality	than	diabetes	developed	after	breast	cancer	
diagnosis.	Taking	Insulin	was	associated	with	a	0.578	(0.554-0.603	95%	CI)	times	higher	hazard	
of	breast	cancer	specific	mortality	than	not	taking	insulin.	Taking	diabetic	pills	was	associated	
with	a	0.706	(0.684-0.730	95%	CI)	times	lower	hazard	of	breast	cancer	specific	mortality	than	
not	taking	diabetic	pills.		
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Table	4.11:	Adjusted	Multivariate	Breast	Cancer	Specific	Mortality	
Model	 Variable		 Hazard	Ratio	 95%	Confidence	Interval	
Model	1:	Women	with	
Breast	Cancer			
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
---	
1.827	
0.738	
	
--	
(1.688-1.978)	
(0.684-0.797)	
	 Race	
			White	
			African-American/Black	
	
---	
1.269	
	
---	
(1.228-1.312)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0	
---	
0.740	
0.929	
	
(0-1.17e8)	
---	
(0.662-0.697)	
(0.904-0.954)	
	 Ever	Been	Diagnosed	
With	Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.375	
0	
--------	
	
	
(1.577-1.630)	
0-1.131e24)	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
1.177	
--------	
	
(1.138-1.217)	
Model	2:	Women	with	
Diabetes	and	Breast	
Cancer	
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
------	
5.289	
.	
	
-------	
(4.762-5.874)	
.	
	 Race	
			White	
			African-American/Black	
	
-------	
1.564	
	
------	
(1.465-1.669	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0	
--------	
0.857	
1.021	
	
(0-8.00e7)	
------------------	
(0.814-0.902)	
(0.971-1.075)	
	 Years	of	Diabetes	Prior	to	
Cancer	Diagnosis	
			Developed	After	
			<	5	years	
			5-10	years	
			10+	years	
	
	
	
----	
0.102	
0.507	
0.599	
	
	
	
---	
(0.090-0.116	
(0.469-0.549)	
(0.565-0.634)	
	 Taking	Insulin	
			Yes	
			No	
	
0.274	
---	
	
(0.257-0.292)	
---	
	 Taking	Diabetic	Pills	
			Yes	
			No	
	
0.344	
---	
	
(0.314-0.373)	
---	
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Table	4.11	displays	the	adjusted	hazard	ratios	of	breast	cancer	specific	mortality	and	
accompanying	95%	confidence	intervals	for	specified	covariates	of	two	cox	proportional	
hazards	models,	one	conducted	using	all	women	with	breast	cancer,	and	the	other	using	only	
women	with	both	breast	cancer	and	diabetes.	
Model	1	was	conducted	using	all	women	with	breast	cancer.	Controlling	for	all	other	co-
variates,	the	age	category	of	35-64	was	associated	with	a	1.827	(1.688-1.978	95%	CI)	times	
higher	hazard	of	breast	cancer	specific	mortality	than	the	18-34	age	group.	Similarly,	the	age	
category	of	65+	was	associated	with	a	0.738	(0.684-0.797	95%	CI)	times	lower	hazard	of	breast	
cancer	specific	mortality	than	the	18-34	age	group.	Controlling	for	all	other	co-variates,	the	
racial	classification	of	African-American/Black	was	associated	with	a	1.269	(1.228-1.312	95%	CI)	
times	higher	hazard	of	breast	cancer	specific	mortality	than	the	racial	classification	of	White.	
Controlling	for	all	other	co-variates,	the	BMI	categories	of	underweight,	overweight,	and	obese,	
were	associated	with	a	0	(0-1.17e8	95%	CI)	times,	0.740	(0.662-0.697	95%	CI)	times	lower,	and	
0.929	(0.904-0.954	95%	CI)	times	lower	hazard	of	breast	cancer	specific	mortality	than	the	BMI	
category	of	normal	weight	respectively.	Controlling	for	all	other	co-variates,	those	who	
reported	being	diagnosed	with	diabetes	and	those	who	reported	being	diagnosed	with	
borderline	diabetes	were	associated	with	a	1.340	(1.305-1.375	95%	CI)	and	0	(0-1.131e24	95%	
CI)	respectively,	times	higher	hazard	of	breast	cancer	specific	mortality	than	those	without	
diabetes.	Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	associated	with	a	1.177	
(1.138-1.217	95%	CI)	times	higher	hazard	of	breast	cancer	specific	mortality	than	diabetes	
developed	after	cancer	diagnosis.		
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Model	2	was	conducted	using	only	women	with	both	breast	cancer	and	diabetes.	
Controlling	for	all	other	covariates,	the	age	category	of	35-64	was	associated	with	a	5.289	
(4.762-5.874	95%	CI)	times	higher	hazard	of	breast	cancer	specific	mortality	than	the	18-34	age	
group.	Due	to	a	lack	of	sufficient	data,	no	hazard	ratio	was	produced	for	the	65+	age	group.	
Controlling	for	all	other	co-variates,	the	racial	classification	of	African-American/Black	was	
associated	with	a	1.564	(1.465-1.669	95%	CI)	times	higher	hazard	of	breast	cancer	specific	
mortality	than	the	racial	classification	of	White.	Controlling	for	all	other	co-variates,	the	BMI	
categories	of	underweight,	overweight,	and	obese,	were	associated	with	a	0	(0-8.00e7		95%	CI)	
times,	0.857	(0.814-0.902	95%	CI)	times	lower,	and	1.021	(0.971-1.075	95%	CI)	times	higher	
hazard	of	breast	cancer	specific	mortality	than	the	BMI	category	of	normal	weight	respectively.	
Controlling	for	all	other	co-variates,	having	diabetes	for	up	to	5	years	prior	to	cancer	diagnosis	
was	associated	with	a	0.102	(0.090-0.116	95%	CI)	times	lower	hazard	of	breast	cancer	specific	
mortality	than	developing	diabetes	after	breast	cancer	diagnosis.		Having	diabetes	for	5-10	
years,	and	10+	years	prior	to	diagnosis	with	breast	cancer	were	associated	with	0.507	(0.469-
0.549	95%	CI)	and	0.599	(0.565-0.634	95%	CI)	respectively	times	lower	hazard	of	breast	cancer	
specific	mortality	than	diabetes	developed	after	breast	cancer	diagnosis.	.	Controlling	for	all	
other	co-variates,	taking	Insulin	was	associated	with	a	0.274	(0.257-0.292	95%	CI)	times	lower	
hazard	of	breast	cancer	specific	mortality	than	not	taking	insulin.	Controlling	for	all	other	co-
variates,	taking	diabetic	pills	was	associated	with	a	0.344	(0.314-0.373	95%	CI)	times	lower	
hazard	of	breast	cancer	specific	mortality	than	not	taking	diabetic	pills.		
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Table	4.12:	Adjusted	Multivariate	Racially	Stratified	Mortality		
	 	 White	 African-American/Black	
Model	 Variable		 Hazard	Ratio	(95%	CI)	 Hazard	Ratio	(95%	CI)	
Model	1:	All-Cause	
Mortality	
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
---	
2.853	(2.641-3.081)	
2.397	(2.226-2.581)	
	
.	
---	
1.050	(0.999-1.104)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0.838	(0.803-0.874)	
---	
0.759	(0.747-0.772)	
1.041	(1.023-1.059)	
	
0.877	(0.764-1.006)	
---	
0.046	(0.040-0.053)	
0.047	(0.041-0.054)	
	 Ever	Been	Diagnosed	
With	Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.377	(1.353-1.402)	
1.001	(0.939-1.067)	
--------	
	
	
15.575	(14.156-17.136)	
.	
----	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
1.079	(1.055-1.105)	
--------	
	
13.658	(12.443-14.992)	
---	
Model	2:	Breast	Cancer	
Specific	Mortality	
	 	 	
	 Age	Category		
			18-34	
			35-64	
			65+	
	
---	
1.845	(1.703-2.000)	
0.753	(0.698-0.813)	
	
.	
---	
0.190		(0.175-0.206)	
	 BMI	Category	
			Underweight	
			Normal	
			Overweight	
			Obese	
	
0	(0-2.365e14)	
---	
0.698	(0.679-0.718)	
1.024	(0.996-1.052)	
	
0	(0-3.664e35)	
---	
0.020	(0.017-0.023)	
0.010	(0.009-0.012)	
	 Ever	Been	Diagnosed	
With	Diabetes	
			Yes	
			Borderline	
			No	
	
	
1.125	(1.093-1.158)	
0	(0-4.9e23)	
---	
	
	
10.891	(9.763-12.150)	
.	
---	
	 Pre-existing	Diabetes	
			Yes	
			No	
	
0.850	(0.818-0.884)	
---	
	
7.696	(6.936-8.540)	
---	
	 	 	 	
	
	 Table	4.12	displays	the	racially	stratified	adjusted	hazard	ratios	of	breast	cancer	specific	
mortality	and	all-cause	mortality	with	accompanying	95%	confidence	intervals	for	the	specified	
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covariates	in	models	conducted	using	all	women	with	breast	cancer.	Model	1	assesses	all-cause	
mortality	as	an	endpoint.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	
age	category	of	35-64	was	associated	with	a	2.853	(2.641-3.081	95%	CI)	times	higher	and	the	
65+	age	category	was	associated	with	a	2.397	(2.226-2.581	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	the	18-34	age	group,	among	white	women.	Controlling	for	all	
other	covariates,	the	BMI	category	of	underweight	was	associated	with	a	0.838	(0.803-0.874	
95%	CI)	time	lower	and	the	BMI	category	of	overweight	was	associated	with	a	0.759	(0.747-
0.772	95%	CI)	times	lower	hazard	of	mortality	from	any	cause	than	the	BMI	category	of	normal	
weight	among	white	women.	The	BMI	category	of	Obese	was	associated	with	a	1.041	(1.023-
1.059	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	than	the	BMI	category	of	normal	
weight	among	white	women.	Controlling	for	all	other	co-variates,	diabetes	diagnosis	was	
associated	with	1.377	(1.353-1.402	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	
than	not	having	a	diabetes	diagnosis,	among	white	women.	Controlling	for	all	other	co-variates,	
pre-existing	diabetes	was	associated	with	a	1.079	(1.055-1.105	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	not	having	pre-existing	diabetes,	among	white	women.		
	 Due	to	a	lack	of	sufficient	data,	the	18-34	age	group	was	not	used	as	the	referent	group	
among	black	women.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	age	
category	of	65+	was	associated	with	a	1.050	(1.703-2.000	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	the	35-64	age	group,	among	African-American/Black	women.	
Controlling	for	all	other	covariates,	the	BMI	categories	of	underweight,	overweight,	and	obese	
were	associated	with	a	0.877	(0.764-1.006	95%	CI),	0.046	(0.040-0.053	95%	CI),	and	0.047	
(0.041-0.054	95%	CI)	respectively,	times	lower	hazard	of	mortality	from	any	cause	that	the	BMI	
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category	of	normal,	among	African-American/Black	women.	Controlling	for	all	other	co-
variates,	diabetes	diagnosis	was	associated	with	a	15.575	(14.156-17.136	95%	CI)	times	higher	
hazard	of	mortality	from	any	cause	than	not	having	a	diabetes	diagnosis,	among	black	women.	
Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	associated	with	a	13.658	(12.443-
14.992	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	than	not	having	pre-existing	
diabetes,	among	African-American/Black	women.		
	 Model	2	assesses	breast	cancer	specific	mortality	as	an	endpoint.	Controlling	for	BMI,	
diabetes	diagnosis,	and	pre-existing	diabetes	the	age	category	of	35-64	was	associated	with	a	
1.845	(1.703-2.000	95%	CI)	times	higher	and	the	65+	age	category	was	associated	with	a	0.753		
(0.698-0.813	95%	CI)	times	lower	hazard	of	mortality	from	breast	cancer	than	the	18-34	age	
group,	among	white	women.	Controlling	for	all	other	covariates,	the	BMI	category	of	
underweight	was	associated	with	a	0	(0-2.365e14	95%	CI)	time	lower	and	the	BMI	category	of	
overweight	was	associated	with	a	0.698	(0.679-0.718	95%	CI)	times	lower	hazard	of	mortality	
from	breast	cancer	than	the	BMI	category	of	normal	weight	among	white	women.	The	BMI	
category	of	Obese	was	associated	with	a	1.024	(0.996-1.052	95%	CI)	times	higher	hazard	of	
mortality	from	breast	cancer	than	the	BMI	category	of	normal	weight	among	white	women.	
Controlling	for	all	other	co-variates,	diabetes	diagnosis	was	associated	with	1.125	(1.093-1.158	
95%	CI)	times	higher	hazard	of	mortality	from	breast	cancer	than	not	having	a	diabetes	
diagnosis,	among	white	women.	Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	
associated	with	a	0.850	(0.818-0.884	95%	CI)	times	lower	hazard	of	mortality	from	breast	
cancer	than	not	having	pre-existing	diabetes,	among	white	women.	
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Due	to	a	lack	of	sufficient	data,	the	18-34	age	group	was	not	used	as	the	referent	group	
among	black	women.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	age	
category	of	65+	was	associated	with	a	0.190		(0.175-0.206	95%	CI)	times	lower	hazard	of	
mortality	from	breast	cancer	than	the	35-64	age	group,	among	African-American/Black	women.	
Controlling	for	all	other	covariates,	the	BMI	categories	of	underweight,	overweight,	and	obese	
were	associated	with	a	0	(0-3.664e35	95%	CI),	0.020	(0.017-0.023	95%	CI),	and	0.010	(0.009-
0.01295%	CI)	respectively,	times	lower	hazard	of	mortality	from	breast	cancer	that	the	BMI	
category	of	normal,	among	African-American/Black	women.	Controlling	for	all	other	co-
variates,	diabetes	diagnosis	was	associated	with	a	10.891	(9.763-12.150	95%	CI)	times	higher	
hazard	of	mortality	from	breast	cancer	than	not	having	a	diabetes	diagnosis,	among	black	
women.	Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	associated	with	a	7.696	
(6.936-8.540	95%	CI)	times	higher	hazard	of	mortality	from	breast	cancer	than	not	having	pre-
existing	diabetes,	among	African-American/Black	women.		
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Chapter	V	
Discussion	
The	Data	abstracted	from	the	2006-2009	NHIS	adult	surveys	showed	that	generally,	
African-American/Black	women	and	White	women	differ	in	their	prevalence	of	characteristics	
of	interest	regarding	diabetes	and	cancer.	White	women	are	older,	have	lower	BMIs	and	
smaller	proportions	that	can	be	considered	overweight	(26.61%)	or	obese	(29.45%),	and	a	
lower	prevalence	of	diabetes	(8.10%)	than	African-American/Black	women	(27.82%overweight,	
44.58%	obese,	12.68%	diabetic).	However,	White	women	had	a	higher	prevalence	of	general	
cancer	(11.21%)	as	well	as	breast	cancer	(3.18%)	than	African-American/Black	women	(4.67%	
and	1.69%)	respectively.	This	data	closely	resembles	the	general	trend	of	current	CDC	estimates	
of	obesity	prevalence	among	adult	White	women	(35.5%)	and	black	women	(56.9%)	and	
diabetes	prevalence	among	adult	White	(5.3%)	and	African-American/Black	women	(9.9%)	(CDC	
2014).		
	Among	women	with	diabetes,	across	both	racial/ethnic	groups,	individuals	were	older,	had	
higher	BMIs,	and	higher	rates	of	both	cancer	and	breast	cancer	than	the	general	female	
population.	However,	among	women	with	diabetes,	African-American/Black	women	showed	
trends	of	being	of	a	younger	age,	being	diagnosed	with	diabetes	earlier,	and	higher	proportions	
being	considered	obese.	Additionally,	African-American/Black	women	had	higher	proportions	
of	women	taking	medication	to	treat	their	diabetes	in	the	form	of	Insulin	or	diabetic	pills	than	
their	white	counterparts.		
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Women	with	breast	cancer	were	older	than	the	general	population,	with	similar	distributions	of	
BMI	categories	and	higher	prevalence	of	diabetes.	The	prevalence	of	diabetes	in	the	general	
population	of	women	was	8.10%	for	white	women	and	12.68%	for	African-American/Black	
women,	compared	to	13.87%	and	33.20%	for	White	and	African-American/Black	women	with	
breast	cancer.	This	indicates	that	diabetes	is	a	much	larger	concern	for	cancer	patients	than	the	
general	population,	especially	among	African-American/Black	women.	Among	women	with	
breast	cancer,	African-American/Black	women	were	younger,	diagnosed	with	breast	cancer	
younger,	had	higher	BMIs,	and	several	times	magnitude	higher	prevalence	of	diabetes	than	
White	women.		
	
Diabetes	and	Pre-existing	Diabetes	Rates	
				The	first	research	question	assessed	in	this	study	was	“Does	Diabetes	and	pre-existing	
diabetes	occurs	at	a	different	rate	among	African-American	women	with	breast	cancer	than	
White	women?”.	Statistical	analysis	showed	that	African-American/Black	women	with	did,	in	
fact,	have	a	higher	prevalence	of	diabetes	than	White	women	(33.20%	v	13.87%,	p	<0.0001).	
This	would	appear	to	be	intuitive	given	diabetes	higher	background	prevalence	in	the	general	
population	of	African-American	women	in	this	study	(12.68%),	however	the	prevalence	among	
women	with	breast	cancer	is	nearly	3	times	higher	than	the	prevalence	of	diabetes	in	the	
general	population	of	African-American	women	in	this	study	and	most	recent	CDC	estimates	
(9.9%).	Comparatively,	among	White	women,	the	prevalence	of	diabetes	also	increased	from	
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the	general	population	(8.10%)	to	the	population	of	White	women	with	breast	cancer	(13.87%),	
but	not	to	the	same	magnitude.		
				Among	women	with	breast	cancer	and	diabetes,	the	rate	of	pre-existing	diabetes	was	higher	
among	African-American/Black	women	than	in	White	women	(52.24%	v	39.82%,	p	<0.0001).	
There	was	no	significant	difference	in	mean	years	of	diabetes	prior	to	breast	cancer	diagnosis,	
however	higher	proportions	of	African-American	women	reported	having	diabetes	for	5-10	
years	(15.28%)	and	>10	years	(26.83%)	prior	to	breast	cancer	diagnosis	than	White	women	
(8.40%	and	17.54%	respectively).	Because	breast	cancer	develops	over	an	extended	period	of	
time,	pre-existing	diabetes	for	significant	lengths	of	time	suggests	a	biological	interaction	
between	the	diabetic	state	and	the	formation	of	breast	cancer.	Although	the	presence	of	
diabetes	5+	years	prior	to	breast	cancer	diagnosis	may	suggest	that	diabetes	played	a	role	in	
the	incipiency,	diabetes	at	any	stage	prior	to	diagnosis	may	still	impact	the	malignancy	by	
accelerating	the	growth	of	the	tumor.	This	study’s	findings	that	a	higher	proportion	of	African-
American/Black	women	with	breast	have	diabetes	(33.20%)	than	White	women	with	breast	
cancer	(13.87%)	supports	previous	studies	in	the	literature	that	suggest	that	breast	cancer	
patients	with	diabetes	are	more	likely	to	be	of	non-white	racial/ethnic	groups	(J.	Luo,	et	al.,	
2015)	although	the	magnitude	differs	significantly	from	what	has	been	put	forth,	5.5%	of	White	
women	with	breast	cancer	having	diabetes	and	11.3%	of	African-American/Black	(Wu,	et	al.,	
2015).		
Diabetes	and	All-Cause/Breast	Cancer	Specific	Mortality	
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The	next	set	of	research	questions	addressed	whether	diabetes	and	pre-existing	diabetes	is	
associated	with	increased	all-cause	and	breast	cancer-specific	mortality.	In	the	adjusted	Cox	
proportional	hazard	model	for	all-cause	mortality	among	all	women	with	breast	cancer,	
diabetes	was	associated	with	an	increased	hazard	of	death	from	any	cause	(HR:	1.603,	1.577-
1.630	95%	CI).	Among	diabetic	women	with	breast	cancer,	pre-existing	diabetes	was	associated	
with	an	increased	hazard	of	death	from	any	cause	(HR:	1.157,	1.109-1.206	95%	CI).		
Overall,	diabetes	increases	the	risk	of	all-cause	mortality.	This	study	identified	a	hazard	ratio	of	
1.603.	Studies	by	(J.	Luo,	et	al.,	2015)	also	identified	similar	increased	risks	of	all-cause	mortality	
(HR:	1.57),	another	study	identified	an	adjusted	HR	of	1.26(need	to	find	citation).	BMI	is	
associated	with	increased	mortality	at	all	categories.	Interestingly,	underweight	has	the	highest	
hazard	ratio	compared	to	normal	weight.	Although	higher	BMI	could	indicate	additional	health	
problems	that	are	associated	with	obesity,	including	more	severe	diabetes,	weight	loss	is	also	a	
result	of	both	cancer	progression	and	cancer	treatment.		
In	the	adjusted	Cox	proportional	hazard	model	for	breast	cancer	specific	mortality	among	all	
women	with	breast	cancer,	diabetes	was	associated	with	an	increased	hazard	of	death	from	
any	cause	(HR:	1.340,	1.305-1.375	95%	CI).	Among	diabetic	women	with	breast	cancer,	pre-
existing	diabetes	did	not	meet	stepwise	model	selection	criteria.	However,	among	all	women	
with	breast	cancer,	pre-existing	diabetes	was	associated	with	an	increased	risk	of	breast	cancer-
specific	mortality	as	well	(HR:	1.177,	1.138-1.217	95%	CI).		
Few	studies	have	been	conducted	on	the	relationship	between	breast	cancer-specific	mortality	
and	diabetes.	A	recently	conducted	study	using	the	WHI	identified	an	insignificant	relationship	
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between	diabetes	and	breast	cancer-specific	mortality,	HR:	.74	(0.52-1.02	95%	CI)	(J.	Luo,	et	al.,	
2014).	Conversely,	this	study	identified	a	significant	relationship	between	diabetes	and	breast	
cancer-specific	mortality,	HR:	1.375.	Studies	have	found	that	women	with	diabetes	are	more	
likely	to	have	hormone	negative	tumors	and	advanced	tumor	stage,	which	is	a	plausible	
explanation	the	increase	in	breast	cancer	specific	mortality.	However,	the	significance	of	race	as	
a	factor	even	among	diabetic	breast	cancer	patients	may	indicate	that	other	factors	in	the	
environment,	behaviors,	or	genetic	biology	of	African-American	women	lead	to	more	
aggressive	malignancies.		
	
	
Race	and	All-Cause/Breast	Cancer	Specific	Mortality	
				The	next	set	of	research	questions	addressed	the	impact	of	race	on	all-cause	and	breast	
cancer-specific	mortality.	In	the	adjusted	Cox	proportional	hazard	model	for	all-cause	mortality	
among	all	women	with	breast	cancer,	the	racial	classification	of	African-American/Black	was	
associated	with	an	increased	hazard	of	death	from	any	cause.	African-American/Black	women	
were	10%	more	likely	(HR:	1.102,	1.076-1.130	95%	CI)	to	die	from	any	cause	when	compared	to	
White	women.	Among	diabetic	women	with	breast	cancer,	African-American	women	were	less	
likely	to	die	from	any	cause	(HR:	0.741,	0.711-0.773	95%	CI).		
				In	the	adjusted	Cox	proportional	hazard	model	for	breast	cancer	specific	mortality	among	all	
women	with	breast	cancer,	African-American/Black	women	were	27%	more	likely	(HR:	1.269,	
1.228-1.312	95%	CI)	to	die	from	breast	cancer	than	White	women.	Among	diabetic	women	with	
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breast	cancer,	African-American/Black	women	were	56%	more	likely	(HR:	1.564,	1.465-1.669	
95%	CI)	to	die	from	breast	cancer	than	White	women.		
				Throughout	the	literature,	an	increase	in	mortality	has	been	shown	for	African-American	
women	compared	to	White	women.	However,	this	study	showed	a	differential	effect	of	race,	
increasing	the	risk	of	death	from	all-causes	in	African-American	women	compared	to	White	
women,	yet	decreasing	that	risk	among	diabetic	patients.	However,	the	hazard	ratio	of	
mortality	from	breast	cancer	increased	from	1.269	(all	breast	cancer	patients)	to	1.564	(diabetic	
breast	cancer	patients)	indicating	that	diabetes	impacts	the	progression	of	cancer,	and	
furthermore	that	impact	has	a	greater	impact	on	African-American	women.	This	may	be	due	to	
many	factors	including	differences	in	treatment	and	differences	in	cancer	biology.		
Impact	of	Diabetes	on	All-Cause	and	Breast	Cancer	Specific	Mortality	among	White	Women	v	
Black	Women	
Diabetes,	Race,	and	All-Cause/Breast	Cancer	Specific	Mortality	
				The	final	set	of	research	questions	assessed	how	the	impact	of	diabetes	differed	on	the	all-
cause	and	breast	cancer-specific	mortality	between	African-American	and	White	women.	The	
models	run	by	stratifying	breast	cancer	specific	and	all-cause	mortality	by	racial	classification	
(Table	4.12)	showed	that	diabetes	diagnosis	does	significantly	raise	the	risk	of	mortality	for	
both	African-American	and	White	women.	However,	diabetes	and	pre-existing	diabetes	show	
differential	effects	across	each	race.	Both	diabetes	and	pre-existing	diabetes	increase	the	risk	of	
all-cause	mortality	in	each	race.	However,	the	magnitude	is	several	times	larger	for	African	
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American	women	(adjusted	Diabetes	HR:	15.575,	adjusted	Pre-existing	HR:	13.658)	than	for	
White	women	(adjusted	Diabetes	HR:	1.377,	adjusted	Pre-existing	HR:	1.079).		
				In	the	modeling	of	breast	cancer-specific	mortality	stratified	by	race,	diabetes	was	shown	to	
increase	the	risk	of	mortality	for	both	races;	however,	pre-existing	diabetes	conferred	a	
protective	effect	on	white	breast	cancer	patients	while	increasing	mortality	risk	for	African-
American	breast	cancer	patients.	Similar	to	the	model	of	all-cause	mortality,	the	association	of	
diabetes	and	pre-existing	diabetes	with	breast	cancer-specific	mortality	was	several	times	
larger	for	African	American	women	(adjusted	Diabetes	HR:	1.891,	adjusted	Pre-existing	
HR:7.696)	than	it	was	for	White	women	(adjusted	Diabetes	HR:	1.125,	adjusted	Pre-existing	HR:	
0.850).		
Strengths	and	Limitations	
Weaknesses	in	this	study:	This	study	is	based	on	the	NHIS	which	is	a	self-report	survey	and	is	
subject	to	recall	bias	as	well	as	classification	error.		Studies	using	cancer	registries	would	be	
more	accurate	and	verifiable	as	well	as	more	comprehensive	in	reporting	of	cancer	
characteristics.	This	study	was	unable	to	control	for	characteristics	of	breast	cancer	that	may	
impact	mortality,	such	as	histology,	stage,	and	hormone	receptor	status.	This	study	was	unable	
to	assess	breast	cancer	treatments	and	how	these	may	impact	survival.		Because	the	NHIS	is	
meant	to	provide	estimates	on	the	prevalence	of	health-related	characteristics	in	the	US,	this	
data	could	not	adequately	assess	the	incidence	of	breast	cancer	among	diabetics.	Additionally,	
this	study	was	unable	to	abstract	information	such	as	education,	income,	and	health	insurance	
status	that	may	impact	treatment	and	diagnosis	of	both	breast	cancer	and	diabetes.		
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BMI	in	this	study	is	at	the	time	of	survey	not	at	the	time	of	diagnosis	with	cancer,	so	BMI	may	
be	influenced	by	cancer	progression	and	/or	lifestyle	changes	made	by	the	individual.	
Strengths	in	this	study:	At	the	time	the	analysis	was	done,	this	was	one	of	2	studies	to	assess	
how	diabetes	affects	mortality	in	African-American/Black	women.	The	NHIS	is	designed	to	be	
nationally	representative,	so	this	study	provides	robust	estimates	of	the	prevalence	of	the	
selected	characteristics	and	statistical	significance	of	the	associations	identified.		
	
Implications	
Diabetes	is	highly	prevalent	among	African-American/Black	breast	cancer	patients.	Moreover,	
African-American/Black	women	are	more	likely	to	have	pre-existing	diabetes	upon	breast	
cancer	diagnosis	than	White	women.	Diabetes	increases	both	all-cause	and	breast	cancer-
specific	mortality	among	both	African-American/Black	and	White	breast	cancer	patients.	
However,	it	appears	to	increase	the	disparity	in	hazard	of	death	between	the	two	racial	groups.	
Diabetes	may	develop	in	individuals	who	already	have	breast	cancer.	However,	Pre-existing	
diabetes	is	a	significant	contributor	to	mortality	from	all	causes	as	well	as	breast	cancer	
specifically.	Thus,	prevention	and	control	of	diabetes	may	help	slow	the	progression	of	breast	
cancer	and	decrease	the	likelihood	of	mortality,	particularly	among	African-American	women.		
Additionally,	specified	treatment	guidelines	may	be	needed	for	diabetic	breast	cancer	patients	
to	aid	in	mitigating	the	increased	mortality	among	this	group.		
Future	studies	
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				Case-Control	studies	could	be	conducted	to	ascertain	if	diabetes	associated	with	the	
development	of	more	aggressive	sub-types	of	breast	cancer.	This	study	and	others	showed	that	
diabetes	is	associated	with	an	increase	in	cancer	mortality;	however,	the	exact	mechanism	
remains	unclear.	Additionally,	longitudinal	studies	on	black	women’s	health	can	be	used	to	
assess	the	incidence	of	breast	cancer	among	both	diabetics	and	non-diabetics.	Studies	that	link	
to	SEER	registries	for	better	accuracy.	Future	studies	would	also	include	clinical	follow-ups	to	
assess	how	controlled	and	uncontrolled	diabetes	impact	mortality,	and	BMI	at	the	time	of	
cancer	diagnosis.	Future	studies	could	also	analyze	the	impact	of	diabetes	on	treatment	
selection	and	treatment	outcomes.	
Conclusion	
This	study	contributes	significantly	to	the	literature	by	providing	additional	data	on	the	co-
morbidity	of	diabetes	and	breast	cancer.	Specifically,	this	study	assessed	the	impact	this	co-
morbidity	has	on	African-American/Black	women.		African-American/Black	women	have	
disproportionately	high	breast	cancer	mortality	rates,	and	by	identifying	the	role	that	a	
common	co-morbidity	may	have	on	that	mortality	rate,	this	study	contributes	to	the	body	of	
literature	aimed	at	decreasing	this	disparity.	Interventions	aimed	at	decreasing	the	prevalence	
of	diabetes	among	breast	cancer	patients	and	emphasis	on	controlling	diabetic	severity	among	
breast	cancer	patients,	specifically	African-Americans	may	lead	to	improvements	in	prognosis.	
Additionally,	this	study	added	to	the	literature	indicating	that	diabetic	medication	may	have	a	
protective	effect	on	all-cause	and	breast	cancer-specific	mortality	among	cancer	patients.		
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